Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 93
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mediterranean Diet Is a Predictor of Progression of Subclinical Atherosclerosis in a Mediterranean Population, The ILERVAS Prospective Cohort Study

  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Castro, Eva
  • Farràs-Sallés, Cristina|||0000-0001-5956-4116
  • Torres, Gerard|||0000-0002-1417-7320
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Lecube, Albert|||0000-0001-9684-0183
  • Valdivieso, José Manuel
  • Fernández, Elvira|||0000-0001-5236-1762
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Antentas Peraile, María|||0009-0005-8140-203X
  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Mauricio, Didac|||0000-0002-2868-0250
Atherosclerotic cardiovascular disease remains a major health issue, often developing silently as subclinical atherosclerotic disease (SAD). The Mediterranean diet (MDiet) is known for its cardiovascular benefits, but the combined influence of both MDiet adherence and physical activity (PA) on SAD progression has not been previously documented. Objective: We aimed to investigate how adherence to a healthy lifestyle, defined as MDiet adherence and PA level, influences SAD progression in subjects from the ILERVAS cohort follow-up. Methods: A study on 3097 participants from the ILERVAS prospective cohort was conducted. MDiet adherence was assessed using the MEDAS score, and PA categories were established using the IPAQ, both categorized into low, moderate, and high levels. Two different lifestyle scores integrating the MDiet and PA categories were built. The presence of atherosclerotic plaques was assessed by carotid and femoral ultrasound examination. Demographic, clinical, and biochemical data were also obtained. Multivariable linear, logistic, and Poisson regression models adjusted for potential confounders were used to analyze the association between the lifestyle scores and SAD progression, as well as the MDiet and PA as separate variables and number of territories with plaque. Results: A healthier lifestyle score did not show an effect on SAD progression. However, a higher MEDAS score was associated with a 3% decrease in the number of territories with plaque (IRR 0.97, 95% CI 0.96-0.99, p < 0.001), suggesting a protective effect of the adherence to the MDiet. PA did not show a significant association (IRR 1.00, 95% CI 1.00-1.00, p = 0.269). Older age, hypertension, dyslipidemia, smoking, and lower eGFR were associated with SAD progression, while the female sex was protective (IRR 0.67, 95% CI 0.63-0.72, p < 0.001). Conclusions: The findings of this study show that higher adherence to the MDiet is associated with reduced incidence of SAD, indicating its potential role in cardiovascular prevention strategies. Although a higher lifestyle score or physical activity levels did not show any significant effect, promoting the MDiet, alongside managing traditional cardiovascular risk factors, could be an effective public health intervention to prevent atherosclerosis and reduce the burden of cardiovascular disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d, An orphan category in Banff classification with cytotoxic T and natural killer cell infiltration

  • Buxeda, Anna|||0000-0001-7305-3259
  • Llinàs Mallol, Laura|||0000-0003-4696-3331
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Arias Cabrales, Carlos E.|||0000-0002-1729-8152
  • Burballa, Carla|||0000-0002-0091-1459
  • Puche, Adrian
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Yélamos, José|||0000-0003-1195-1496
  • Vilches, Carlos|||0000-0002-0300-9225
  • Naesens, Maarten|||0000-0002-5625-0792
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Pascual, Julio|||0000-0002-4735-7838
  • Crespo, Marta|||0000-0001-6992-6379
Isolated microvascular inflammation (iMVI) without HLA donor-specific antibodies or C4d deposition in peritubular capillaries remains an enigmatic phenotype that cannot be categorized as antibody-mediated rejection (ABMR) in recent Banff classifications. We included 221 kidney transplant recipients with biopsies with ABMR (n = 73), iMVI (n = 32), and normal (n = 116) diagnoses. We compared peripheral blood leukocyte distribution by flow cytometry and inflammatory infiltrates in kidney transplant biopsies among groups. Flow cytometry showed fewer lymphocytes and total, CD4, and CD8 peripheral T cells in iMVI compared with ABMR and normal cases. ABMR and iMVI had fewer total natural Killer (NK) cells but more NKG2A NK cells. Immunohistochemistry indicated that ABMR and iMVI had greater CD3 and CD68 glomerular infiltration than normal biopsies, whereas CD8 and TIA1 cells showed only increased iMVI, suggesting they are cytotoxic T cells. Peritubular capillaries displayed more CD3, CD56, TIA1, and CD68 cells in both ABMR and iMVI. In contrast, iMVI had less plasma cell infiltration in peritubular capillaries and interstitial aggregates than ABMR. iMVI displayed decreased circulating T and NK cells mirrored by T cell and NK cell infiltration in the renal allograft, similar to ABMR. However, the lesser plasma cell infiltration in iMVI may suggest an antibody-independent underlying stimulus.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and molecular spectrum of v-lesion

  • Buxeda, Anna|||0000-0001-7305-3259
  • Crespo, Marta|||0000-0001-6992-6379
  • Chamoun, Betty|||0000-0002-4267-2273
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Torres, Irina B.|||0000-0003-3304-0810
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Burballa, Carla|||0000-0002-0091-1459
  • Pascual, Julio|||0000-0002-4735-7838
  • Mengel, Michael|||0000-0002-7222-3356
  • Adam, Benjamin|||0000-0003-1908-1739
  • Pérez-Sáez, María José|||0000-0002-8601-2699
Isolated v-lesion presents diagnostic stratification and clinical challenges. We characterized allograft outcomes for this entity based on posttransplant time (early: ≤1 month vs late:.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease, possibly the least silent cause of chronic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Furlano, Monica|||0000-0003-1025-3901
Pain is the highest prioritized patient-reported outcome in people with autosomal dominant polycystic kidney disease (ADPKD) but it remains infrequently and inconsistently measured across countries, studies and trials. The study by El-Damanawi et al. integrated a network of ADPKD expert clinicians, pain specialists, researchers and patient representatives from the national UK PKD charity, with the aim of addressing the lack of validated ADPKD-specific pain assessment tools (APATs). The APAT designed by the authors included several pain measurement tools and was tested in ADPKD patients, although further validation through assessment in larger cohorts is needed. Establishing a standardized instrument for pain measurement will ensure that pain is measured and reported in a consistent way to inform decision-making and identify effective interventions aimed at managing pain and minimizing the impact pain has on patients with ADPKD. In this context, the APAT established by the authors is to be warmly welcomed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inherited kidney disease and CAKUT are common causes of kidney failure requiring kidney replacement therapy, an ERA Registry study

  • Ortiz, Alberto|||0000-0002-9805-9523
  • Kramer, A.|||0000-0002-7560-2669
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Rodríguez Arévalo, Olga Lucia|||0009-0002-1442-3883
  • Gjerstad, A.C.
  • Santiuste, C.
  • Trujillo-Alemán, S.
  • Ferraro, Pietro Manuel|||0000-0002-1379-022X
  • Methven, S.
  • Santamaría, Rafael
  • Naumovic, R.
  • Resic, H.
  • Hommel, K.
  • Segelmark, M.|||0000-0002-1221-0772
  • Ambühl, P.M.
  • Sorensen, S. S.
  • Parmentier, C.
  • Vidal, E.
  • Bakkaloglu, S.A.|||0000-0001-6530-9672
  • Plumb, L.
  • Palsson, R.
  • Kerschbaum, J.|||0000-0002-6896-2279
  • ten Dam, M.A.G.J.
  • Stel, V.S.|||0000-0002-0007-1947
  • Jager, Kitty|||0000-0003-0444-8569
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background. Inherited kidney diseases (IKDs) and congenital anomalies of the kidney and urinary tract (CAKUT) are causes of kidney failure requiring kidney replacement therapy (KRT) that major renal registries usually amalgamate into the primary renal disease(PRD) category 'miscellaneous' or in the glomerulonephritis or pyelonephritis categories. This makes IKDs invisible (except for polycystic kidney disease) and may negatively influence the use of genetic testing, which may identify a cause for IKDs and some CAKUT. Methods. We re-examined the aetiology of KRT by composing a separate IKD and CAKUT PRD group using data from the European Renal Association (ERA) Registry. Results. In 2019, IKD-CAKUT was the fourth most common cause of kidney failure among incident KRT patients, accounting for 8.9% of cases [IKD 7.4% (including 5.0% autosomal dominant polycystic kidney disease), CAKUT 1.5%], behind diabetes (23.0%), hypertension (14.4%) and glomerulonephritis (10.6%). IKD-CAKUT was the most common cause of kidney failure among patients <20 years of age (41.0% of cases), but their incidence rate was highest among those ages 45-74 years (22.5 per million age-related population). Among prevalent KRT patients, IKD-CAKUT (18.5%) and glomerulonephritis (18.7%) were the two most common causes of kidney failure overall, while IKD-CAKUT was the most common cause in women (21.6%) and in patients <45 years of age (29.1%). Conclusion. IKD and CAKUT are common causes of kidney failure among KRT patients. Distinct categorization of IKD and CAKUT better characterizes the epidemiology of the causes of chronic kidney disease (CKD) and highlights the importance of genetic testing in the diagnostic workup of CKD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pyridazino-pyrrolo-quinoxalinium salts as highly potent and selective leishmanicidal agents targeting trypanothione reductase

  • de Lucio, H.
  • García-Marín, Javier
  • Sánchez-Alonso, Patricio
  • García-Soriano, Juan Carlos
  • Toro, Miguel Ángel
  • Vaquero, Juan J.
  • Gago, Federico
  • Alajarín, Ramón
  • Jimenez-Ruiz, Antonio
Fifteen pyridazino-pyrrolo-quinoxalinium salts were synthesized and tested for their antiprotozoal activity against Leishmania infantum amastigotes. Eleven of them turned out to be leishmanicidal, with EC values in the nanomolar range, and displayed low toxicity against the human THP-1 cell line. Selectivity indices for these compounds range from 10 to more than 1000. Compounds 3b and 3f behave as potent inhibitors of the oxidoreductase activity of the essential enzyme trypanothione disulfide reductase (TryR). Interestingly, binding of 3f is not affected by high trypanothione concentrations, as revealed by the noncompetitive pattern of inhibition observed when tested in the presence of increasing concentrations of this substrate. Furthermore, when analyzed at varying NADPH concentrations, the characteristic pattern of hyperbolic uncompetitive inhibition supports the view that binding of NADPH to TryR is a prerequisite for inhibitor-protein association. Similar to other TryR uncompetitive inhibitors for NADPH, 3f is responsible for TryR-dependent reduction of cytochrome c in a reaction that is typically inhibited by superoxide dismutase., This research was funded by the Spanish MICINN (Projects PID2019-104070RB-C22 and PCTQ2017-85263-R), the Comunidad de Madrid (Project PLATESA2-CM ref S-2018/BAA-4370 and NOV- ELREN, B2017/BMD-3751) and the Instituto de Salud Carlos III (FEDER funds, RETIC REDINREN RD16/0009/0015). The University of Alcalá and the Spanish Ministry for Culture and Education are gratefully acknowledged for the predoctoral fellowship (FPU16/1647) to J. G.-M. The University of Alcalá is also gratefully acknowledged for the FPU grants to P. S. A. and J. C. G.-S. and the postdoctoral fellowship to H. d. L.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reciprocal regulation between the molecular clock and kidney injury

  • Rey-Serra, Carlos
  • Tituaña, Jessica
  • Lin, Terry
  • Herrero, José Ignacio
  • Miguel, Verónica
  • Barbas, Coral
  • Meseguer, Anna
  • Ramos, Ricardo
  • Chaix, Amandine
  • Panda, Satchidananda
  • Lamas Peláez, Santiago
Tubulointerstitial fibrosis is the common pathological substrate for many etiologies leading to chronic kidney disease. Although perturbations in the circadian rhythm have been associated with renal disease, the role of the molecular clock in the pathogenesis of fibrosis remains incompletely understood. We investigated the relationship between the molecular clock and renal damage in experimental models of injury and fibrosis (unilateral ureteral obstruction, folic acid, and adenine nephrotoxicity), using genetically modified mice with selective deficiencies of the clock components Bmal1, Clock, and Cry. We found that the molecular clock pathway was enriched in damaged tubular epithelial cells with marked metabolic alterations. In human tubular epithelial cells, TGFβ significantly altered the expression of clock components. Although Clock played a role in the macrophage-mediated inflammatory response, the combined absence of Cry1 and Cry2 was critical for the recruitment of neutrophils, correlating with a worsening of fibrosis and with a major shift in the expression of metabolism-related genes. These results support that renal damage disrupts the kidney peripheral molecular clock, which in turn promotes metabolic derangement linked to inflammatory and fibrotic responses., This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-104233RB-100/AEI/10.13039/501100011033 (S Lamas), Instituto de Salud Carlos III REDinREN RD12/0021/0009 and RD16/0009/0016 (S Lamas), Comunidad de Madrid “NOVELREN” B2017/BMD-3751 and INNOREN P2022/BMD-7221 (S Lamas and C Barbas), and Fundación Renal “Iñigo Alvarez de Toledo” (S Lamas), all from Spain. C Rey-Serra has been the recipient of an FPI research training contract from the Spanish Research State Agency (BES-2016-076735). The CBMSO receives institutional support from Fundación “Ramón Areces.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation

  • Campillo, Sofía
  • Bohorquez, Lourdes
  • Gutiérrez-Calabrés, Elena
  • García-Ayuso, Diego
  • Frutos, Sergio de
  • Rodríguez-Puyol, Manuel
  • Rodríguez-Puyol, Diego
  • Calleros, Laura
Cardiovascular disease is an important cause of death in patients with chronic kidney disease (CKD). Protein-bound uremic toxins, such as p-cresyl and indoxyl sulfate (IS), are poorly removed during hemodialysis, leading to vascular endothelial dysfunction and leukocyte extravasation. These processes can be related to dynamic adhesion structures called podosomes. Several studies have indicated the role of integrin-linked kinase (ILK) in the accumulation of integrin-associated proteins in podosomes. Here, we investigated the involvement of ILK and podosome formation in the adhesion and extravasation of monocytes under p-cresol (pc) and IS exposure. Incubation of THP-1 human monocyte cells with these toxins upregulated ILK kinase activity. Together, both toxins increased cell adhesion, podosome formation, extracellular matrix degradation, and migration of THP-1 cells, whereas ILK depletion with specific small interfering RNAs suppressed these processes. Interestingly, F-actin colocalized with cortactin in podosome cores, while ILK was colocalized in podosome rings under toxin stimulation. Podosome Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) and AKT protein depletion demonstrated that monocyte adhesion depends on podosome formation and that the ILK/AKT signaling pathway is involved in these processes. Ex vivo experiments showed that both toxins induced adhesion and podosome formation in leukocytes from wild-type mice, whereas these effects were not observed in leukocytes of conditional ILK-knockdown animals. In summary, under pc and IS stimulation, monocytes increase podosome formation and transmigratory capacity through an ILK/AKT signaling pathway-dependent mechanism, which could lead to vascular injury. Therefore, ILK could be a potential therapeutic target for the treatment of vascular damage associated with CKD., This work was supported by co-funded grants from the Instituto de Salud Carlos III (ISCIII) and FEDER funds (PI17/01513, PI17/00625, PI20/00634, PI20/00664, RETIC REDinREN program RD16/0009/0018), Madrid Community funds (B2017/BMD-3751), and University of Alcalá and FRIAT funds.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

  • Opazo-Ríos, Lucas
  • Tejera-Muñoz, Antonio
  • Soto Catalan, Manuel
  • Marchant, Vanessa
  • Mas Fontao, Sebastián
  • Lavoz, Carolina
  • Moreno, Juan Antonio
  • Fierro Fernandez, Marta
  • Ramos, Ricardo
  • Suarez-Alvarez, Beatriz
  • López-Larrea, Carlos
  • Ruiz-Ortega, Marta
  • Egido, Jesús
  • Rodrigues-Díez, Raúl R.
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high residual risk of disease progression to end-stage renal failure. To further understand the pathogenesis of tissue injury in this disease, by means of the Next-Generation Sequencing, we have studied the microRNA (miRNA) differential expression pattern in kidneys of Black and Tan Brachyury (BTBR) ob/ob (leptin deficiency mutation) mouse. This experimental model of type 2 diabetes and obesity recapitulates the key histopathological features described in advanced human DN and therefore can provide potential useful translational information. The miRNA-seq analysis, performed in the renal cortex of 22-week-old BTBR ob/ob mice, pointed out a set of 99 miRNAs significantly increased compared to non-diabetic, non-obese control mice of the same age, whereas no miRNAs were significantly decreased. Among them, miR-802, miR-34a, miR-132, miR-101a, and mir-379 were the most upregulated ones in diabetic kidneys. The in silico prediction of potential targets for the 99 miRNAs highlighted inflammatory and immune processes, as the most relevant pathways, emphasizing the importance of inflammation in the pathogenesis of kidney damage associated to diabetes. Other identified top canonical pathways were adipogenesis (related with ectopic fatty accumulation), necroptosis (an inflammatory and regulated form of cell death), and epithelial-to-mesenchymal transition, the latter supporting the importance of tubular cell phenotype changes in the pathogenesis of DN. These findings could facilitate a better understanding of this complex disease and potentially open new avenues for the design of novel therapeutic approaches to DN., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/ 00119, PI17/01495, PI17/00130, PI20/00140, PI19/00184, PI20/00639, PI20/00487, PI20/00375, DTS20/00083, and DTS19/00093), Red de Investigación Renal REDINREN: RD16/0009 to MR-O (RD16/0009/0003) and to CL-L (RD16/0009/0020), Sociedad Española de Nefrología, “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to MR-O), “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN 2019-103294 to MR-O), Innovation programme under the Marie SkłodowskaCurie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699 to MR-O), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017- 22369), Consejería de Salud y Familias-FEDER, Junta de Andalucía (PIGE-0052-2020 to JM), and Gobierno de Chile (S-2020-05 VIDCA-UACh to CL). RICORS program to RICORS2040 (KIDNEY DISEASE) RD21/0005/0002 to MRO; RD21/0005/0017 to CL-L.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Graphene-Based Bioactive Product with a Non-Immunological Impact on Mononuclear Cell Populations from Healthy Volunteers

  • Lavín-López, María del Prado
  • Torres-Torresano, Mónica
  • García-Cuesta, Eva María
  • Soler Palacios, Blanca
  • Griera, Mercedes
  • Martínez-Rovira, Martín
  • Martínez-Rovira, José Antonio
  • Rodríguez-Puyol, Diego
  • Frutos, Sergio de
We previously described GMC, a graphene-based nanomaterial obtained from carbon nanofibers (CNFs), to be biologically compatible and functional for therapeutic purposes. GMC can reduce triglycerides’ content in vitro and in vivo and has other potential bio-functional effects on systemic cells and the potential utility to be used in living systems. Here, immunoreactivity was evaluated by adding GMC in suspension at the biologically functional concentrations, ranging from 10 to 60 µg/mL, for one or several days, to cultured lymphocytes (T, B, NK), either in basal or under stimulating conditions, and monocytes that were derived under culture conditions to pro-inflammatory (GM-MØ) or anti-inflammatory (M-MØ) macrophages. All stirpes were obtained from human peripheral mononuclear cells (PBMCs) from anonymized healthy donors. The viability (necrosis, apoptosis) and immunological activity of each progeny was analyzed using either flow cytometry and/or other analytical determinations. A concentration of 10 to 60 µg/mL GMC did not affect lymphocytes’ viability, either in basal or active conditions, during one or more days of treatment. The viability and expression of the inflammatory interleukin IL-1β in the monocyte cell line THP-1 were not affected. Treatments with 10 or 20 µg/mL GMC on GM-MØ or M-MØ during or after their differentiation process promoted phagocytosis, but their viability and the release of the inflammatory marker activin A by GM-MØ were not affected. A concentration of 60 µg/mL GMC slightly increased macrophages’ death and activity in some culture conditions. The present work demonstrates that GMC is safe or has minimal immunological activity when used in suspension at low concentrations for pre-clinical or clinical settings. Its biocompatibility will depend on the dose, formulation or way of administration and opens up the possibility to consider GMC or other CNF-based biomaterials for innovative therapeutic strategies., This work was supported partially by co-funded grants from the Instituto de Salud Carlos III (ISCIII), Comunidad de Madrid, Universidad de Alcala and FEDER funds: PI17/01513, PI17/00625, PI20/00634, PI23/01071, P2022/BMD7221 and B2017/BMD3751; the RETIC REDinREN and RICORS 2040 programs (RD16/0009/0018; RD21/0005/0023; RD24/0004/0020); INNOREN-CM and NOVELREN-CM; PIUAH23/CCS-010; and art.60 LOSU 2022/024. GMC sponsored part of this research financially through the acquisition of reagents and small laboratory equipment., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

  • Cruzado, J.M.
  • Lauzurica, R.
  • Pascual, J.
  • Marcen, R.
  • Moreso, F.
  • Gutierrez-Dalmau, A.
  • Andrés, A.
  • Hernández, D.
  • Torres, A.
  • Beneyto, M.I.
  • Melilli, E.
  • Manonelles, A.
  • Arias, M.
  • Praga, M.
Introduction: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. Methods: This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium <10 mg/dl were randomized to paricalcitol (PAR) or calcifediol (CAL). The intention-to-treat population (PAR: n = 46; CAL: n = 47) was used for the analysis. The primary endpoint was the percentage of patients with serum iPTH >110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. Results: The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH <70 pg/ml in the PAR group than in the CAL group (63.4% vs. 37.2%; P = 0.03). No differences were observed in bone turnover biomarkers and bone mineral density. The estimated glomerular filtration rate was significantly higher in the CAL group than in the PAR group without differences in albuminuria. In protocol biopsies, interstitial fibrosis and tubular atrophy tended to be higher in the PAR group than in the CAL group (48% vs. 23.8%; P = 0.09). Both medications were well tolerated. Conclusion: Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation hyperparathyroidism.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort

  • Valls, Joan
  • Perez-Guallar, Carles
  • Cambray, Serafi
  • Perez-Guallar, Carles
  • Bozic, Milica
  • Bermudez-Lopez, Marcelino
  • Fernandez, Elvira
  • Betriu, Angels
  • Rodriguez, Isabel
  • Valdivielso, Jose M.
  • Aladren Regidor, Ma Jose
  • Almirall, Jaume
  • Ponz, Esther
  • Arteaga Coloma, Jesus
  • Bajo Rubio, Ma Auxiliadora
  • Diaz, Raquel Raquel
  • Belart Rodriguez, Montserrat
  • Gascon, Antonio
  • Bover Sanjuan, Jordi
  • Bronsoms Artero, Josep
  • Cabezuelo Romero, Juan B.
  • Muray Cases, Salome
  • Calvino Varela, Jesus
  • Caro Acevedo, Pilar
  • Carreras Bassa, Jordi
  • Cases Amenos, Aleix
  • Masso Jimenez, Elisabet
  • Moreno Lopez, Rosario
  • Cigarran Guldris, Secundino
  • Lopez Prieto, Saray
  • Comas Mongay, Lourdes
  • Comerma, Isabel
  • Compte Jove, Ma Teresa
  • Cuberes Izquierdo, Marta
  • de Alvaro, Fernando
  • Hevia Ojanguren, Covadonga
  • de Arriba de la Fuente, Gabriel
  • del Pino y Pino, Ma Dolores
  • Diaz-Tejeiro Izquierdo, Rafael
  • Ahijado Hormigos, Francisco
  • Dotori, Marta
  • Duarte, Veronica
  • Estupinan Torres, Sara
  • Fernandez Reyes, Ma Jose
  • Fernandez Rodriguez, Ma Loreto
  • Fernandez, Guillermina
  • Galan Serrano, Antonio
  • Garcia Canton, Cesar
  • Garcia Herrera, Antonio L.
  • Garcia Mena, Mercedes
  • Gil Sacaluga, Luis
  • Aguilar, Maria
  • Gorriz, Jose Luis
  • Huarte Loza, Emma
  • Lerma, Jose Luis
  • Liebana Canada, Antonio
  • Marin Alvarez, Jesus Pedro
  • Martin Alemany, Nadia
  • Martin Garcia, Jesus
  • Martinez Castelao, Alberto
  • Martinez Villaescusa, Maria
  • Martinez, Isabel
  • Moina Eguren, Inigo
  • Moreno Los Huertos, Silvia
  • Mouzo Mirco, Ricardo
  • Munar Vila, Antonia
  • Munoz Diaz, Ana Beatriz
  • Navarro Gonzalez, Juan F.
  • Nieto, Javier
  • Carreno, Agustin
  • Novoa Fernandez, Enrique
  • Ortiz, Alberto
  • Fernandez, Beatriz
  • Paraiso, Vicente
  • Perez Fontan, Miguel
  • Peris Domingo, Ana
  • Pinera Haces, Celestino
  • Prados Garrido, Ma Dolores
  • Prieto Velasco, Mario
  • Puig Mari, Carmina
  • Rivera Gorrin, Maite
  • Rubio, Esther
  • Ruiz, Pilar
  • Salgueira Lazo, Mercedes
  • Martinez Puerto, Ana Isabel
  • Sanchez Tomero, Jose Antonio
  • Sanchez, Jose Emilio
  • Sans Lorman, Ramon
  • Saracho, Ramon
  • Sarrias, Maria
  • Seron, Daniel
  • Soler, Maria Jose
  • Barrios, Clara
  • Sousa, Fernando
  • Toran, Daniel
  • Tornero Molina, Fernando
  • Uson Carrasco, Jose Javier
  • Valera Cortes, Ildefonso
  • Vilaprinyo del Perugia, Ma Merce
  • Virto Ruiz, Rafael C.
  • Santos Altozano, Carlos
  • Artigao Rodenas, Miguel
  • Gil Gil, Ines
  • Adan Gil, Francisco
  • Garcia Criado, Emilio
  • Dura Belinchon, Rafael
  • Fernandez Toro, Jose Ma
  • Divison Garrote, Juan Antonio
Chronic kidney disease (CKD) is a major risk factor for end-stage renal disease, cardiovascular disease and premature death. Despite classical clinical risk factors for CKD and some genetic risk factors have been identified, the residual risk observed in prediction models is still high. Therefore, new risk factors need to be identified in order to better predict the risk of CKD in the population. Here, we analyzed the genetic association of 79 SNPs of proteins associated with mineral metabolism disturbances with CKD in a cohort that includes 2, 445 CKD cases and 559 controls. Genotyping was performed with matrix assisted laser desorption ionizationtime of flight mass spectrometry. We used logistic regression models considering different genetic inheritance models to assess the association of the SNPs with the prevalence of CKD, adjusting for known risk factors. Eight SNPs (rs1126616, rs35068180, rs2238135, rs1800247, rs385564, rs4236, rs2248359, and rs1564858) were associated with CKD even after adjusting by sex, age and race. A model containing five of these SNPs (rs1126616, rs35068180, rs1800247, rs4236, and rs2248359), diabetes and hypertension showed better performance than models considering only clinical risk factors, significantly increasing the area under the curve of the model without polymorphisms. Furthermore, one of the SNPs (the rs2248359) showed an interaction with hypertension, being the risk genotype affecting only hypertensive patients. We conclude that 5 SNPs related to proteins implicated in mineral metabolism disturbances (Osteopontin, osteocalcin, matrix gla protein, matrix metalloprotease 3 and 24 hydroxylase) are associated to an increased risk of suffering CKD.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Kidney transplant from controlled donors following circulatory death: Results from the GEODAS-3 multicentre study

  • Portolés, J.M.
  • Pérez-Sáez, M.J.
  • López-Sánchez, P.
  • Lafuente-Covarrubias, O.
  • Juega, J.
  • Hernández, D.
  • Espí, J.
  • Navarro, M.D.
  • Mazuecos, M.A.
  • Rodríguez-Ferrero, M.L.
  • Maruri-Kareaga, N.
  • Moreso, F.
  • Melilli, E.
  • de Souza, E.
  • Ruiz, J.C.
  • Llamas, F.
  • Gutiérrez-Dalmau, A.
  • Guirado, L.
  • Martín-Moreno, P.
  • Pérez Flores, I.
  • Fernández-García, A.
  • Jiménez, C.
  • Gavela, E.
  • Ramos, A.
  • Pascual, J.
  • On, behalf, of, the, grupo, GEODAS
Introduction: Many European countries have transplant programs with controlled donors after cardiac death (cDCD). Twenty-two centers are part of GEODAS group. We analyzed clinical results from a nephrological perspective. Methods: Observational, retrospective and multicentre study with systematic inclusion of all kidney transplant recipients from cDCD, following local protocols regarding extraction and immunosuppression. Results: A total of 335 cDCD donors (mean age 57.2 years)whose deaths were mainly due to cardiovascular events were included. Finally, 566 recipients (mean age 56.5 years; 91.9% first kidney transplant)were analyzed with a median of follow-up of 1.9 years. Induction therapy was almost universal (thymoglobulin 67.4%; simulect 32.8%)with maintenance with prednisone-MMF-tacrolimus (91.3%)or combinations with mTOR (6.5%). Mean cold ischemia time (CIT)was 12.3 h. Approximately 3.4% (n = 19)of recipients experienced primary non-function, essentially associated with CIT (only CIT = 14 h was associated with primary non-function). Delayed graft function (DGF)was 48.8%. DGF risk factors were CIT = 14 h OR 1.6, previous haemodialysis (vs. peritoneal dialysis)OR 2.1 and donor age OR 1.01 (per year). Twenty-one patients (3.7%)died with a functioning graft, with a recipient and death-censored graft survival at 2-years of 95% and 95.1%, respectively. The estimated glomerular filtration rate at one year of follow-up was 60.9 ml/min. Conclusions: CIT is a modifiable factor for improving the incidence of primary non-function in kidney transplant arising from cDCD. cDCD kidney transplant recipients have higher delayed graft function rate, but the same patient and graft survival compared to brain-dead donation in historical references. These results are convincing enough to continue fostering this type of donation. Introducción: Varios países europeos disponen de programas de donación tras parada cardiaca controlada (cDCD). Veintidós centros participan en el grupo GEODAS, cuyos resultados clínicos presentamos desde una perspectiva nefrológica. Métodos: Estudio multicéntrico retrospectivo observacional con inclusión sistemática de todos los trasplantes renales (TR) procedentes de cDCD, siguiendo protocolos locales de extracción e inmunosupresión. Resultados: Se incluyó a 335 donantes tras cDCD (edad media 57, 2 años) fallecidos mayoritariamente por eventos cardiovasculares. Se analizan 566 receptores (edad media de 56, 5 años; el 91, 9% con primer trasplante renal), con una mediana de seguimiento de 1, 9 años. La terapia de inducción fue casi universal (timoglobulina 67, 4%; simulect 32, 8%) con mantenimiento con prednisona-MMF-tacrolimus (91, 3%) o combinaciones con mTOR (6, 5%). El tiempo medio de isquemia fría (CIT) fue 12, 3 h. Hubo un 3, 4% de fallo primario del injerto (n = 19), asociado fundamentalmente al tiempo de isquemia fría (solo el CIT = 14 h se asoció a fallo primario del injerto). La función retrasada del injerto (DGF) fue 48, 8%. Los factores de riesgo para la DGF fueron: CIT = 14 h OR 1, 6, procedencia de hemodiálisis (vs. diálisis peritoneal) OR 2, 1 y edad del donante OR 1, 01 (por año). Veintiún pacientes fallecieron con injerto funcionante (3, 7%), con una supervivencia de paciente e injerto (censurada para muerte) al segundo año del 95% y del 95, 1%, respectivamente. El filtrado glomerular estimado al año de seguimiento fue 60, 9 ml/min. Conclusiones: El CIT es un factor modificable para mejorar la incidencia del fallo primario del injerto en trasplante renal procedente de cDCD. El trasplante renal con cDCD tiene mayor incidencia en la función retrasada del injerto, pero igual supervivencia de paciente e injerto que la referencia histórica para donación en muerte encefálica. Los resultados son satisfactorios para continuar promoviendo este tipo de donación.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value – a multi-centre cohort study

  • Puig-Gay, N.
  • Jacobs-Cacha, C.
  • Sellarès, J.
  • Guirado, L.
  • González Roncero, F.
  • Jiménez, C.
  • Zárraga, S.
  • Paul, J.
  • Lauzurica, R.
  • Alonso, Á.
  • Fernández, A.
  • Beneyto, I.
  • Mazuecos, A.
  • Hernández, D.
  • Rodriguez-Benot, A.
  • Franco, A.
  • Jimeno, L.
  • Crespo, M.
  • Meseguer, A.
  • Moreso, F.
  • Seron, D.
  • Lopez-Hellin, J.
  • Cantarell, C.
Recurrence of idiopathic focal segmental glomerulosclerosis (FSGS) is a serious complication after kidney transplantation. FSGS relapse is suspected by a sudden increase in proteinuria but there is not an accurate noninvasive diagnostic tool to confirm this entity or to detect patients at risk. We aimed to validate the diagnostic performance of ApoA-Ib to detect FSGS relapses by measuring urinary ApoA-Ib in a retrospective cohort of 61 kidney transplanted patients (37 FSGS and 24 non-FSGS). In addition, to assess the ApoA-Ib predictive ability, ApoA-Ib was measured periodically in a prospective cohort of 13 idiopathic FSGS patients who were followed during 1 year after transplantation. ApoA-Ib had a sensitivity of 93.3% and a specificity of 90.9% to diagnose FSGS relapses, with a high negative predictive value (95.2%), confirming our previous results. In the prospective cohort, ApoA-Ib predated the recurrence in four of five episodes observed. In the nonrelapsing group (n = 9), ApoA-Ib was negative in 37 of 38 samples. ApoA-Ib has the potential to be a good diagnostic biomarker of FSGS relapses, providing a confident criterion to exclude false positives even in the presence of high proteinuria. It has also the potential to detect patients at risk of relapse, even before transplantation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal

  • López, V.
  • Vázquez, T.
  • Alonso-Titos, J.
  • Cabello, M.
  • Alonso, A.
  • Beneyto, I.
  • Crespo, M.
  • Díaz-Corte, C.
  • Franco, A.
  • González-Roncero, F.
  • Gutiérrez, E.
  • Guirado, L.
  • Jiménez, C.
  • Jironda, C.
  • Lauzurica, R.
  • Llorente, S.
  • Mazuecos, A.
  • Paul, J.
  • Rodríguez-Benot, A.
  • Ruiz, J.C.
  • Sánchez-Fructuoso, A.
  • Sola, E.
  • Torregrosa, V.
  • Zárraga, S.
  • Hernández, D.
  • Grupo de Estudio GREAT (Grupo Español de Actualizaciones en Trasplante)
La pandemia por coronavirus SARS-CoV-2 (Covid-19) está evolucionando de manera muy rápida y representa un riesgo especial en pacientes inmunodeprimidos y con comorbilidades añadidas. El conocimiento sobre esta infección emergente va también en aumento, si bien, aún sigue habiendo muchas incógnitas, sobre todo en la población con trasplante renal. Este manuscrito presenta una propuesta de actuación con recomendaciones generales y específicas para proteger y prevenir de la infección a esta población tan vulnerable como son los receptores de un trasplante renal.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Direct-Acting Antivirals for the Treatment of Kidney Transplant Patients with Chronic Hepatitis C Virus Infection in Spain: A Long-Term Prospective Observational Study

  • González-Corvillo, C.
  • Beneyto, I.
  • Sánchez-Fructuoso, A.
  • Perelló, M.
  • Alonso, A.
  • Mazuecos, A.
  • Jiménez, C.
  • Zárraga, S.
  • Paul, J.
  • Lauzurica, R.
  • Hernández, D.
  • Guirado, L.
  • Franco, A.
  • Ruiz, J.C.
  • Llorente, S.
  • Crespo, M.
  • Rodríguez-Benot, A.
  • De Gracia Guindo, M.D.C.
  • Díaz-Corte, C.
  • Gentil, M.A.
Background. Direct-Acting antivirals (DAA) allow effective and safe eradication of hepatitis C virus (HCV) in most patients. There are limited data on the long-Term effects of all-oral, interferon-free DAA combination therapies in kidney transplant (KT) patients infected with HCV. Here we evaluated the long-Term tolerability, efficacy, and safety of DAA combination therapies in KT patients with chronic HCV infection. Methods. Clinical data from KT patients treated with DAA were collected before, during, and after the treatment, including viral response, immunosuppression regimens, and kidney and liver function. Results. Patients (N = 226) were mostly male (65.9%) aged 56.1 ± 10.9 years, with a median time from KT to initiation of DAA therapy of 12.7 years and HCV genotype 1b (64.6%). Most patients were treated with sofosbuvir-based therapies. Rapid virological response at 1 month was achieved by 89.4% of the patients and sustained virological response by week 12 by 98.1%. Liver function improved significantly after DAA treatment. Tacrolimus dosage increased 37% from the beginning of treatment (2.5 ± 1.7 mg/d) to 1 year after the start of DAA treatment (3.4 ± 1.9 mg/d, P < 0.001). Median follow-up was 37.0 months (interquartile range, 28.4-41.9) and death-censored graft survival was 91.1%. Adverse events resulting from DAA treatment, especially anemia, were reported for 31.0% of the patients. Conclusions. Chronic HCV infection can be treated efficiently and safely with DAA therapy in KT patients. Most patients retained stable kidney function and improved liver function. Tacrolimus dose had to be increased in most patients, potentially as a result of better liver function.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: A network analysis approach

  • Gil-Berrozpe, Gustavo J.
  • Segura, Alex G.
  • Sánchez-Torres, Ana M.
  • Amoretti, Silvia
  • Giné-Servén, Eloi
  • Vieta, Eduard
  • Mezquida, Gisela
  • Lobo, Antonio
  • Gonzalez-Pinto, Ana
  • Andreu-Bernabeu, Alvaro
  • Roldán, Alexandra
  • Forte, Maria Florencia
  • Castro, Josefina
  • Bergé, Daniel
  • Rodríguez, Natalia
  • Ballesteros, Alejandro
  • Mas, Sergi
  • Cuesta, Manuel J.
  • Bernardo, Miquel
Psychopathological manifestations and cognitive impairments are core features of psychotic disorders. Polygenic risk scores (PRS) offer insights into the relationships between genetic vulnerability, symptomatology, and cognitive impairments. This study used a network analysis to explore the connections between PRS, cognition, psychopathology, and overall functional outcomes in individuals experiencing a first episode of psychosis (FEP). The study sample comprised 132 patients with FEP. Genetic data were used to construct PRS for mental disorders and cognitive traits via PRS-continuous shrinkage. We conducted comprehensive clinical and neuropsychological assessments at 2 months post-diagnosis and again at a 2-year follow-up. A network analysis was performed to generate two distinct networks and their centrality indices, encompassing 19 variables across domains such as symptoms, cognition, functioning, and PRS. Variables were grouped within related domains, and stronger relationships were observed within domains than between them. PRS for schizophrenia showed weak negative associations with attention, working memory, and verbal memory, while PRS for cognitive performance showed weak positive associations with attention. Negative symptoms were negatively associated with functioning and verbal memory at both the 2-month and 2-year assessments, as well as with social cognition at 2 years. Poor functioning was moderately related to greater severity of Positive and Negative Syndrome Scale dimensions. This study identified pathways linking PRS, cognition, symptoms, and functioning, suggesting that genetic risk may serve as a marker of vulnerability and disorder progression. The findings also highlight the importance of considering genetic predispositions alongside clinical and cognitive factors to better understand the heterogeneity of psychotic disorders.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Stress inoculation during adolescence attenuates social stress-induced increase in ethanol intake in adult male mice

  • Reguilón, M.D.
  • Manzanedo, C.
  • Miñarro, J.
  • Rodríguez-Arias, M.
Social stress exposure heightens the risk of substance abuse disorder development, especially when endured during adolescence, influencing long-term mental health. This study investigates early-life stress's potential to confer resilience against later-life stressors. To investigate this hypothesis, we examined the impact of a single social defeat (SD) incident during adolescent mice's lives on subsequent voluntary ethanol consumption following repeated adult social stress exposure. Half of the adolescent mice experienced SD at postnatal day 28. Three weeks later (postnatal day 49), defeated groups encountered four confrontations with aggressive residents every 72 h, while control groups were exposed to non-resident exploration. A day after the last SD, defeated mice were classified as resilient or susceptible based on their response to a social interaction test (SIT), a model for depressive behavior. To assess ethanol consumption during young adulthood, researchers used the ‘drinking in the dark’ and oral ethanol self-administration paradigms. Stress inoculation (IS) slightly increased resilient animals in the SIT. In mice without IS exposure during adolescence, susceptible defeated mice displayed higher ethanol consumption and motivation than control and resilient mice. IS in adolescence effectively counteracted this effect, as IS-SD groups, whether resilient or susceptible, showed no increase in ethanol intake. These groups also exhibited similar motivation to control, measured by the progressive ratio. Notably, elevated IL-6 levels seen in SD-S mice were absent in IS-exposed mice. Additionally, IS-exposed groups had lower prefrontal cortex IL-6 and CX3CL1 levels. These findings support the hypothesis that IS, induced by moderate-intensity stress during adolescence, can enhance resilience to more severe stressors in adulthood.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

  • Vergara Arana, Ander
  • Molina Van den Bosch, Mireia
  • Toapanta Gaibor, Nestor Gabriel
  • Villegas, Andrés
  • Sánchez-Cámara, Luis
  • Soler Romeo, Maria Jose
  • de Sequera, Patricia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiàlisi; Mortalitat, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiálisis; Mortalidad, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haemodialysis; Mortality, Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination., The authors are current recipients of FONDOS DE INVESTIGACIÓN SANITARIA—FEDER (ISCIII) PI17/00257, REDINREN RD16/0009/0030, RD/16/0009/0026, and EIN2020-112338.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

  • Oleas, Diana
  • Bolufer Cardona, Monica
  • Agraz Pamplona, Irene
  • Gabaldon Dominguez, Alejandra
  • Bury, Roxana
  • Espinel Garuz, María Eugenia
  • Serón Micas, Daniel
  • García Carro, Clara
  • Soler Romeo, Maria Jose
  • Muñoz Couselo, Eva
  • Felip Font, Enriqueta
Nefritis intersticial aguda; Inhibidors de punts de control; Biòpsia de ronyó, Nefritis intersticial aguda; Inhibidores de puntos de control; Biopsia renal, Acute interstitial nephritis; Checkpoint inhibitors; Kidney biopsy, Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d’Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, ISCIII (PI17/00257) and Redinren (RD16/0009/0030). M.B. performed this work as the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

  • Vergara Arana, Ander
  • Bermejo Garcia, Sheila
  • Azancot Rivero, M Antonieta
  • Sanchez Fructuoso, Ana Isabel
  • Sánchez de la Nieta, M. Dolores
  • Agraz Pamplona, Irene
  • Soler Romeo, Maria Jose
  • García-Carro, Clara
Malaltia renal crònica; Diabetis mellitus; Malaltia renal diabètica, Enfermedad renal crónica; Diabetes mellitus; Enfermedad renal diabética, Chronic kidney disease; Diabetes mellitus; Diabetic kidney disease, Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder—Instituto de Salud Carlos III (PI17/00257) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

  • Cabrera Perez, Raquel
  • Gámez-Valero, Ana
  • Rojas-Márquez, Raquel
  • Borràs, Francesc Enric
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Monguió-Tortajada, Marta
Cèl·lules estromals mesenquimals; Gelatina de Wharton; Diferenciació osteogènica, Células estromales mesenquimales; Gelatina de Wharton; Diferenciación osteogénica, Mesenchymal stromal cells, Wharton’s jelly; Osteogenic differentiation, Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions., Work in our laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788), Fundació la Marató de TV3 (expedient number: 122831), and ISCIII-REDinREN (RD16/0009 Feder Funds), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational programme (European Regional Development Fund) 2014-2020. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya). Our laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Groups (ref. 2017-SGR-719, 2017-SGR-301 and 2017-SGR-483).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • León Román, Juan
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Vergara Arana, Ander
  • Gabaldon Dominguez, Alejandra
  • Torres Rodriguez, Irina Betsabe
  • Bury, Roxana
  • Baldallo, Cinthia
  • Serón Micas, Daniel
  • Soler Romeo, Maria Jose
COVID-19; Malaltia renal crònica, COVID-19; Enfermedad renal crónica, COVID-19; Chronic kidney disease, Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder (FI17/00257 and EIN2020-1123381) and Redinren (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Safety of Obtaining an Extra Biobank Kidney Biopsy Core

  • Bermejo Garcia, Sheila
  • García Carro, Clara
  • Mast, Richard
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • León Román, Juan
  • Bolufer Cardona, Monica
  • Gabaldon Dominguez, Alejandra
  • Serón Micas, Daniel
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
Biobank; Chronic kidney disease; Kidney biopsy, Biobanco; Enfermedad renal cronica; Biopsia renal, Biobanc; Malaltia renal crònica; Biòpsia de ronyó, Background and objectives: Kidney biopsy (KB) is the “gold standard” for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. Material and methods: Prospective observational study of KBs performed at Vall d’Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications. Results: A total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506–3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (n = 25) required blood transfusion, 1.4% (n = 3) had severe hematomas, 2.3% (n = 5) required embolization, and 0.5% (n = 1) presented arterio-venous fistula. An increased risk for complication was independently associated with obtaining a single kidney core (vs. 2 and 3 cores) (p = 0.021). Conclusions: KB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports., The authors are current recipients of research grant from Red de Investigación Renal (REDINREN, RD16/0009/0030). (RICORS, RD21/0005/0016).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents

  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Beyer, Katrin|||0000-0001-8905-1514
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Extracellular vesicles (EVs) have become an attractive field among the scientific community. Yet, a major challenge is to define a consensus method for EVs isolation. Ultracentrifugation has been the most widely used methodology but rapid methods, including Size Exclusion Chromatography (SEC) and/or precipitating agents such as Polyethylene glycol (PEG) or PRotein Organic Solvent PRecipitation (PROSPR) have emerged. To evaluate the impact of these different methods on the resulting EV preparations, plasma EVs were isolated using SEC, PEG and PROSPR, and their total protein content, NTA and Cryo-electron microscopy profiles, and EV-markers were compared. Also, their effect on recipient cells was tested. Low protein content and Cryo-EM analysis showed that SEC removed most of the overabundant soluble plasma proteins, which were not removed using PEG and partially by PROSPR. Moreover, only SEC allowed the detection of the EV-markers CD9, CD63 and CD81, LGALS3BP and CD5L, suggesting a putative interference of the precipitating agents in the structure/composition of the EVs. Furthermore, PEG and PROSPR-based EV isolation resulted in reduced cell viability in vitro. These results stress that appropriate EV-isolation method should be considered depending on the forthcoming application of the purified EVs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rare diseases, rare presentations, recognizing atypical inherited kidney disease phenotypes in the age of genomics

  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
A significant percentage of adults (10%) and children (20%) on renal replacement therapy have an inherited kidney disease (IKD). The new genomic era, ushered in by the next generation sequencing techniques, has contributed to the identification of new genes and facilitated the genetic diagnosis of the highly heterogeneous IKDs. Consequently, it has also allowed the reclassification of diseases and has broadened the phenotypic spectrum of many classical IKDs. Various genetic, epigenetic and environmental factors may explain 'atypical' phenotypes. In this article, we examine different mechanisms that may contribute to phenotypic variability and also provide case examples that illustrate them. The aim of the article is to raise awareness, among nephrologists and geneticists, of rare presentations that IKDs may show, to facilitate diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization and proteomic profile of extracellular vesicles from peritoneal dialysis efflux

  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Soler Majoral, Jordi|||0000-0001-6693-4859
  • Rubio Esteve, Cristina
  • Lozano Ramos, Sara Inés
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bonet Sol, Josep
  • Troya Saborido, Maria Isabel|||0000-0002-9742-9094
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Peritoneal Dialysis (PD) is considered the best option for a cost-effective mid-term dialysis in patients with Chronic Renal Failure. However, functional failure of the peritoneal membrane (PM) force many patients to stop PD treatment and start haemodialysis. Currently, PM functionality is monitored by the peritoneal equilibration test, a tedious technique that often show changes when the membrane damage is advanced. As in other pathologies, the identification and characterization of extracellular vesicles (EVs) in the peritoneal dialysis efflux (PDE) may represent a non-invasive alternative to identify biomarkers of membrane failure. Using size-exclusion chromatography, we isolated EVs from PDE in a group of patients. Vesicles were characterized by the presence of tetraspanin markers, nanoparticle tracking analysis profile, cryo-electron microscopy and mass spectrometry. Here, we report the isolation and characterization of PDE-EVs. Based on mass spectrometry, we have found a set of well-conserved proteins among patients. Interestingly, the peptide profile also revealed remarkable changes between newly enrolled and longer-treated PD patients. These results are the first step to the identification of PDE-EVs based new markers of PM damage, which could support clinicians in their decision-making in a non-invasive manner.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

  • Torres, Armando|||0000-0003-1121-5173
  • Hernández, Domingo
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • Burgos, María Dolores
  • Pallardó, Luis M.
  • Kanter, Julia
  • Díaz-Corte, Carmen
  • Rodríguez, Minerva
  • Díaz Gómez, Juan Manuel|||0000-0002-5653-6619
  • Silva, Irene|||0000-0002-2723-1031
  • Valdes, Francisco
  • Fernández-Rivera, Constantino
  • Osuna, Antonio
  • Gracia Guindo, María C.
  • Gómez Alamillo, Carlos
  • Ruiz, Juan C.
  • Marrero Miranda, Domingo
  • Pérez-Tamajón, Lourdes
  • Rodríguez, Aurelio
  • González-Rinne, Ana
  • Alvarez, Alejandra
  • Perez-Carreño, Estefanía
  • de la Vega Prieto, María José
  • Henriquez, Fernando
  • Gallego Samper, Roberto
  • Salido, Eduardo
  • Porrini, Esteban
Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunomodulatory effect of MSC on B cells is independent of secreted extracellular vesicles

  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Franquesa, Marcella|||0000-0002-1287-8908
Mesenchymal stem or stromal cells (MSC) have proven immunomodulatory properties toward B cell activation and induce regulatory B cells (Breg), through a dual mechanism of action that relies both on cell contact and secreted factors. One of them are MSC-derived extracellular vesicles (EVs), membrane nanovesicles that mediate cell communication and typically reflect the phenotype of the cell of origin. MSC-EVs could resemble MSC functions, and are being contemplated as an improved alternative to the MSC-based immunomodulatory therapy. In the present work, we focused on the factors secreted by MSC and aimed to elucidate the putative role of MSC-EVs in the immunomodulation of B cells. EVs and soluble protein-enriched fractions (PF) were isolated from MSC-conditioned medium (CM) using size-exclusion chromatography (SEC) and their capacity to modulate B cell activation, induction of Breg and B cell proliferation was compared to that of the whole MSCs. Co-culture with MSC or unfractionated CM induced naïve and CD24hiCD38hi, IL-10 producing (Breg) phenotypes on B cells while not affecting proliferation. MSC-PF had a comparable effect to MSCs, inducing a naïve phenotype, and even though they did not induce the shift toward a CD24hiCD38hi population, MSC-PF fostered IL-10 production by B cells. Conversely, MSC-EVs failed to promote naïve B cells and to reduce memory B cells. MSC-EVs induced CD24hiCD38hi B cells to a similar extent of that of MSC, but not bona fide Bregs since they did not produce IL-10. Our results show that B cell modulation by MSC is partially mediated by soluble factors other than EVs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton's jelly mesenchymal stromal cells, Mechanisms and implications for bioprocess development and clinical application

  • Cabrera-Pérez, Raquel|||0000-0002-4858-0142
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Rojas-Márquez, R.
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Background: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton's jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation, The 2019 Expert Consensus From the Transplantion Society Working Group

  • Schinstock, Carrie A.|||0000-0002-3274-3277
  • Mannon, Roslyn B.|||0000-0003-1776-3680
  • Budde, K
  • Chong, Anita S.
  • Haas, Mark
  • Knechtle, Stuart
  • Lefaucheur, Carmen
  • Montgomery, Robert A.
  • Nickerson, Peter|||0000-0002-7393-7799
  • Tullius, Stefan G.
  • Ahn, Curie
  • Askar, Medhat
  • Crespo, Marta|||0000-0001-6992-6379
  • Chadban, Steven J.
  • Feng, Sandy
  • Jordan, Stanley C.
  • Man, Kwan
  • Mengel, Michael|||0000-0002-7222-3356
  • Morris, Randall E.
  • O'Doherty, Inish
  • Ozdemir, Binnaz H.
  • Seron, Daniel|||0000-0003-2054-653X
  • Tambur, Anat R.
  • Tanabe, Kazunari
  • Taupin, Jean-Luc
  • O'Connell, Philip J.
With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed to improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Recent advances in the clinical management of autosomal dominant polycystic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic systemic disorder causing the development of renal and hepatic cysts and decline in renal function. It affects around 1 in 1,000 live births. Early hypertension and progressive renal failure due to massive enlargement of cysts and fibrosis are hallmarks of the disease. This article reviews recent advances in ADPKD and focuses mainly on diagnosis, management, and prediction of the course of the disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome, case report and review of the literature

  • Domingo, Andrea|||0000-0003-3759-7595
  • Furlano, Monica|||0000-0003-1025-3901
  • Pybus, Marc|||0000-0002-6195-5738
  • Barraca, Daniel
  • Martínez, Ana Belén
  • Mora Muñoz, Emiliano
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
Galloway-Mowat syndrome (GAMOS) is a rare autosomal recessive disorder characterized by early-onset nephrotic syndrome and microcephaly with brain anomalies. WDR73 pathogenic variants were described as the first genetic cause of GAMOS and, very recently, four novel causative genes, OSGEP, LAGE3, TP53RK, and TPRKB, have been identified. We present the clinical and genetic characteristics of two unrelated infants with clinical suspicion of GAMOS who were born from consanguineous parents. Both patients showed a similar clinical presentation, with early-onset nephrotic syndrome, microcephaly, brain atrophy, developmental delay, axial hypotonia, and early fatality. We identified two novel likely disease-causing variants in the OSGEP gene. These two cases, in conjunction with the findings of a literature review, indicate that OSGEP pathogenic variants are associated with an earlier onset of nephrotic syndrome and shorter life expectancy than WDR73 pathogenic variants. Our findings expand the spectrum of pathogenic variants in the OSGEP gene and, taken in conjunction with the results of the literature review, suggest that the OSGEP gene should be considered the main known monogenic cause of GAMOS. Early genetic diagnosis of GAMOS is of paramount importance for genetic counseling and family planning.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gender differences in cancer risk after kidney transplantation

  • Buxeda, Anna|||0000-0001-7305-3259
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Bartolomé-Solanas, Álvaro|||0000-0002-2307-0007
  • Mir, Marisa
  • Pascual-Dapena, Ana
  • Sans, Anna
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
Kidney transplant (KT) recipients are at greater risk of developing some cancers than the general population. Moreover, cancer is the only cause of death that is currently increasing after kidney transplantation. We analyzed incidence, risk factors and characteristics of post-transplant malignancies (solid organ tumors and lymphoproliferative disorders) at our center in 925 KT recipients (1979-2014). Sex differences were particularly assessed. One hundred and eight patients (11.7%) developed solid organ tumors (76.9%) or lymphoma (23.1%). Twenty-one percent of patients who reached 20 years after KT developed cancer, with a median post-KT time to diagnosis of 7.4 years. Most common solid organs affected were lung (30.1%), prostate (10.8%), bladder (9.6%), and native kidney (7.2%). When analyzing standardized incidence ratios (SIR) by gender compared to the general population, relative risk was increased in women (SIR = 1.81; 95%CI, 1.28-2.45) but not significantly increased in men (SIR = 1.22; 0.95-2.52). Regarding specific types, gynecological (SIR = 11.6; 4.2-22.7) and lung (SIR = 10.0; 4.3-18.2) in women, and bladder (SIR = 16.3; 5.9-32.1) in men were the most affected locations. Thymoglobulin, a polyclonal antibody that has been used as an immunosuppressive agent in kidney transplantation over the last decades, was a significant risk factor for developing cancer in adjusted regression analysis [IRR = 1.62, 1.02-2.57; p = 0.041], and was associated with lower patient survival. Compared with the general population, the incidence of post-KT non-skin cancer is almost two-fold higher in women but not significantly higher in men. Lung is the most common solid organ affected. Thymoglobulin induction therapy is associated with a greater risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular profile of urine extracellular vesicles from normo-functional kidneys reveal minimal differences between living and deceased donors

  • Lozano Ramos, Sara Inés
  • Bancu, Ioana|||0000-0002-6799-2169
  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Cañas, Laura
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Bonet Sol, Josep
  • Armengol Barnils, Maria del Pilar|||0000-0002-9423-2966
  • Lauzurica, Ricardo|||0000-0002-8051-5199
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Kidney transplantation (KTx) is the best therapeutic approach for chronic kidney diseases leading to irreversible kidney failure. Considering the origin of the graft, several studies have reported differences between living (LD) and deceased donors (DD) in graft and patient survival. These differences seem to be related to multiple factors including, donor age and time of cold ischemia among others. Many of transplanted organs come from old-aged DDs, in which pre-transplant biopsy is recommended. However, kidney biopsy has several limitations, and there is a need to develop alternatives to assess the status of a kidney before transplantation. As the analysis of urinary extracellular vesicles (uEVs) rendered promising results as non-invasive biomarkers of kidney-related pathologies, this pilot study aimed to investigate whether profiling uEVs of LDs and DDs may be of help to assess the quality of the kidney before nephrectomy. uEVs from 5 living donors and 7 deceased donors were isolated by size-exclusion chromatography, and their protein and miRNA content were analysed by liquid chromatography followed by mass spectrometry and next generation sequencing, respectively. Then, hierarchical clustering and venn diagrams were done with Perseus software and InteractiVenn tool. Specific EVs data bases were also used for Gene Ontology analysis. Next generation sequencing revealed that uEVs from DDs contained less miRNAs than LDs, but most of the DD-expressed miRNAs were shared with LDs (96%). Only miR-326 (targeting the apoptotic-related Bcl2) was found significantly over-represented in LD. Focusing on the protein content, we detected a low intra-group correlation in both types of donors. Despite these differences, hierarchical clustering of either miRNA or protein data could not identify a differential profile between LDs and DDs. Of note, 90% of transplanted patients had a functional graft after a year from KTx. In this pilot study we found that, in normo-functional grafts, minor differences in uEVs profile could not discriminate between LDs and DDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Calle Arias, Alexandra|||0000-0003-3903-5019
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Cserkóová, Adriana
  • Morancho, Anna|||0000-0001-9059-3206
  • Ramírez de Paz, Miguel Ángel|||0000-0002-5868-2134
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rudilla, F..
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impacto de la pandemia COVID-19 en los servicios de Nefrología españoles

  • Soler, María José|||0000-0003-3621-0766
  • Macia Heras, Manuel
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Del Pino Y Pino, Mª Dolores
  • Salgueira Lazo, Mercedes
La pandemia de la infección por el coronavirus tipo 2 del síndrome respiratorio agudo grave o SARS-CoV-2, causante de la enfermedad por coronavirus de 2019 (COVID-19), ha precisado una transformación drástica de los hospitales y, por consiguiente, de los servicios de Nefrología de España. Desde la Sociedad Española de Nefrología se ha realizado una encuesta a los jefes de servicios de Nefrología de España abordando la reorganización de los servicios de Nefrología y la actividad en la época de mayor afectación por COVID-19. Hemos preguntado por la integración de los nefrólogos en equipos COVID-19, la actividad asistencial de hospitalización de Nefrología (ingresos programados, biopsias renales), la realización de cirugías programadas como los accesos vasculares o la implantación de catéteres peritoneales, la suspensión o no del programa de trasplante renal y la transformación de las consultas externas de Nefrología. En el trabajo actual se detallan la adaptación y la transformación de los servicios de Nefrología en la pandemia COVID-19 en España. Durante dicho periodo se han suspendido los ingresos programados en los servicios de Nefrología, la realización de cirugías/biopsias programadas y ha disminuido en más de un 75% el programa de trasplante renal. Es de interés mencionar que las consultas externas de Nefrología se han realizado mayoritariamente telefónicamente. En conclusión, la pandemia ha impactado claramente en la actividad clínica en los servicios de Nefrología españoles disminuyendo la actividad programada y los trasplantes renales y modificando la actividad en consultas externas. Un plan de transformación asistencial e implementación de telemedicina en Nefrología parece necesario y de gran utilidad en un futuro próximo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts

  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Cucchiari, David|||0000-0002-7594-1070
  • Cañas, Laura
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bonet Sol, Josep
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Diekmann, Fritz|||0000-0001-6199-3016
  • Taco, Omar|||0000-0001-9081-5665
  • Lauzurica, Ricardo|||0000-0002-8051-5199
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
In kidney transplantation, fibrosis represents the final and irreversible consequence of the pathogenic mechanisms that lead to graft failure, and in the late stages it irremediably precedes the loss of renal function. The invasiveness of kidney biopsy prevents this condition from being frequently monitored, while clinical data are rather unspecific. The objective of this study was to find noninvasive biomarkers of kidney rejection. We carried out proteomic analysis of the urinary Extracellular Vesicles (uEVs) from a cohort of kidney transplant recipients (n = 23) classified according to their biopsy-based diagnosis and clinical parameters as interstitial fibrosis and tubular atrophy (IFTA), acute cellular rejection (ACR), calcineurin inhibitors toxicity (CNIT) and normal kidney function (NKF). Shotgun mass spectrometry of uEV-proteins identified differential expression of several proteins among these different groups. Up to 23 of these proteins were re-evaluated using targeted proteomics in a new independent cohort of patients (n = 41) classified in the same diagnostic groups. Among other results, we found a differential expression of vitronectin (VTN) in patients displaying chronic interstitial and tubular lesions (ci and ct mean.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COVID-19 in CKD Patients, Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • Román, Juan León
  • García-Carro, Clara|||0000-0002-5130-603X
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Vergara, Ander|||0000-0003-1926-0147
  • Gabaldón, Alejandra
  • Torres, Irina B.|||0000-0003-3304-0810
  • Bury, Roxana
  • Baldallo, Cinthia
  • Seron, Daniel|||0000-0003-2054-653X
  • Soler, María José|||0000-0003-3621-0766
Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Data included patients who underwent kidney biopsy at the Vall d'Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Patients with CO VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of bariatric surgery on cardiac structure and function in obese patients, Role of the renin-angiotensin system

  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Molina, Lluís
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • Sans, Laia
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Vazquez, Susana
  • Benaiges, David|||0000-0001-5411-364X
  • Granados, Ana Marina
  • Ramon, José Manuel
  • Pascual, Julio|||0000-0002-4735-7838
Echocardiographic alterations have been described in obesity, but their modifications after bariatric surgery (BS) and mechanisms are little known, mostly in normotensive patients. We aimed to analyze cardiac changes 1 year post-BS and to explore possible mechanisms. A cohort of patients with severe obesity (58% normotensives) were prospectively recruited and examined before surgery and after 12 months. Clinical and echocardiographic data, 24 h BP, renin-angiotensin-aldosterone system (RAAS) components, cytokines, and inflammatory markers were analyzed at these two time points. Overall reduction in body weight was mean (IQR) = 30.0% (25.9-33.8). There were statistically significant decreases in left ventricle mass index 2.7 (LVMI) 2.7, septum thickness (ST), posterior wall thickness (PWT), relative wall thickness (RWT), and E/e', both in the whole cohort and in patients without RAAS blockers (p ≤.04 for all). Plasma renin activity (PRA) decreased from (median, IQR) = 0.8 (0.3;1.35) to 0.4 (0.2;0.93) ng/ml/h, plasma aldosterone from 92 (58.6;126) to 68.1 (56.2;83.4) ng/dl, and angiotensin-converting enzyme (ACE)-2 activity from 7.7 (5.7;11.8) to 6.8 (5.3;11.2) RFU/µl/h, p <.05. The body weight loss correlated with a decrease in both 24 h SBP and 24 h DBP (Pearson's coefficient 0.353, p =.022 and 0.384, p =.012, respectively). Variation (Δ) of body weight correlated with ΔE/e' (Pearson's coeff. 0.414, p =.008) and with Δ lateral e' (Pearson's coeff. = -0.363, p =.018). Generalized linear models showed that ΔPRA was an independent variable for the final (12-months post-BS) LVMI 2.7 (p =.028). No other changes in cardiac parameters correlated with ΔBP. In addition to the respective baseline value, final values of PWT and RWT were dependent on 12-month Δ of PRA, ACE, and ACE/ACE2 (p <.03 for all). We conclude that there are cardiac changes post-BS in patients with severe obesity, normotensives included. Structural changes appear to be related to modifications in the renin-angiotensin axis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

B Cell-Derived Extracellular Vesicles Reveal Residual B Cell Activity in Kidney Graft Recipients Undergoing Pre-Transplant Desensitization

  • Cucchiari, David|||0000-0002-7594-1070
  • Tubita, Valeria
  • Rovira, Jordi|||0000-0001-8737-5005
  • Ramirez-Bajo, Maria J..
  • Banon-Maneus, Elisenda
  • Lazo-Rodriguez, Marta
  • Hierro-Garcia, Natalia
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Piñeiro, Gastón Julio|||0000-0003-3806-4731
  • Martorell Montserrat, Jaume|||0000-0001-9031-0042
  • Peri, Lluís
  • Musquera, Mireia
  • Hertig, Alexandre
  • Oppenheimer, Federico|||0000-0002-1117-831X
  • Campistol, Josep M..
  • Diekmann, Fritz|||0000-0001-6199-3016
  • Revuelta, Ignacio|||0000-0002-3584-4516
Background: Living-donor kidney transplant (LDKT) recipients undergoing desensitization for Human Leukocyte Antigen (HLA)-incompatibility have a high risk of developing antibody-mediated rejection (ABMR). The purpose of the study is to evaluate if residual B cell activity after desensitization could be estimated by the presence of circulating B cell-derived extracellular vesicles (BEVs). Methods: BEVs were isolated by Sepharose-based size exclusion chromatography and defined as CD19+ and HLA-II+ extracellular vesicles. We analyzed stored serum samples from positive crossmatch LDKT recipients before and after desensitization at first post-transplant biopsy and at 12-month protocol biopsy (n = 11). Control groups were formed by hypersensitized patients who were not submitted to desensitization (n = 10) and by low-risk recipients (n = 9). A prospective validation cohort of 11 patients also included the analysis of B cells subpopulations in recipients' blood and lymph nodes recovered upon graft implantation, along with BEVs analysis before and after desensitization. Results: We found out that CD19+ and HLA-II+BEVs dropped significantly after desensitization and relapse in patients who later developed ABMR was evident. We validated these findings in a proof-of-concept prospective cohort of 6 patients who received the same desensitization protocol and also in a control group of 5 LDKT recipients. In these patients, B cell subpopulations were also studied in recipients' blood and lymph nodes that were recovered before the graft implantation. We confirmed the significant drop in BEVs after desensitization and that this paralleled the reduction in CD19+cells in lymph nodes, while in peripheral blood B cells, this change was almost undetectable. Conclusions: BEVs reflected B cell residual activity after desensitization and this could be a valid surrogate of humoral alloreactivity in this setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes

  • Palau, Vanesa|||0000-0002-3210-7924
  • Jarrín, Josué|||0000-0001-9172-3383
  • Villanueva, Sofia
  • Benito, David|||0000-0001-5413-5005
  • Márquez, Eva
  • Rodríguez García, Eva
  • Soler, María José|||0000-0003-3621-0766
  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Sans, Laia|||0000-0002-3628-9489
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Barrios, Clara|||0000-0003-0492-4107
  • Riera Oliva, Marta|||0000-0003-4362-7965
Disintegrin and metalloproteinase domain 17 (ADAM17) activates inflammatory and fibrotic processes through the shedding of various molecules such as Tumor Necrosis Factor-α (TNF-α) or Transforming Growht Factor-α (TGF-α). There is a well-recognised link between TNF-α, obesity, inflammation, and diabetes. In physiological situations, ADAM17 is expressed mainly in the distal tubular cell while, in renal damage, its expression increases throughout the kidney including the endothelium. The aim of this study was to characterize, for the first time, an experimental mouse model fed a high-fat diet (HFD) with a specific deletion of Adam17 in endothelial cells and to analyse the effects on different renal structures. Endothelial Adam17 knockout male mice and their controls were fed a high-fat diet, to induce obesity, or standard rodent chow, for 22 weeks. Glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, macrophage infiltration, and galectin-3 levels were evaluated. Results showed that obese mice presented higher blood glucose levels, dysregulated glucose homeostasis, and higher body weight compared to control mice. In addition, obese wild-type mice presented an increased albumin-to-creatinine ratio; greater glomerular size and mesangial matrix expansion; and tubular fibrosis with increased galectin-3 expression. Adam17 deletion decreased the albumin-to-creatinine ratio, glomerular mesangial index, and tubular galectin-3 expression. Moreover, macrophage infiltration in the glomeruli of obese Adam17 knockout mice was reduced as compared to obese wild-type mice. In conclusion, the expression of ADAM17 in endothelial cells impacted renal inflammation, modulating the renal function and histology in an obese pre-diabetic mouse model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies, The Influence of TAC Exposure and Metabolism

  • Chamoun, Betty|||0000-0002-4267-2273
  • Torres, Irina B.|||0000-0003-3304-0810
  • Gabaldón, Alejandra
  • Sellarés Nadal, Joana
  • Perelló, Manel|||0000-0003-1859-5279
  • Castellà Fernández, Eva
  • Guri, Xavier
  • Salcedo, Maite
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C), coefficient of variation of tacrolimus (CV-TAC-C), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C at the time of biopsy as well as CV-TAC-C, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50-0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01-1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25-0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24-0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improvement of Arterial Stiffness One Month after Bariatric Surgery and Potential Mechanisms

  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Galceran, Isabel
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • Vázquez, Susana
  • Sans, Laia|||0000-0002-3628-9489
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Benaiges, David|||0000-0001-5411-364X
  • Pascual, Julio|||0000-0002-4735-7838
Arterial stiffness (AS) is an independent predictor of cardiovascular risk. We aimed to analyze changes (Δ) in AS 1-month post-bariatric surgery (BS) and search for possible pathophysiological mechanisms. Patients with severe obesity (43% hypertensives) were prospectively evaluated before and 1-month post-BS, with AS assessed by pulse-wave velocity (PWV), augmentation index (AIx@75) and pulse pressure (PP). Ambulatory 24 h blood pressure (BP), anthropometric data, renin-angiotensin-aldosterone system (RAAS) components and several adipokines and inflammatory markers were also analyzed. Overall reduction in body weight was mean (interquartile range (IQR)) = 11.0% (9.6-13.1). A decrease in PWV, AIx@75 and PP was observed 1-month post-BS (all, p < 0.01). There were also significant Δ in BP, RAAS components, adipokines and inflammatory biomarkers. Multiple linear regression adjusted models showed that Δaldosterone was an independent variable (B coeff.95%CI) for final PWV (B = -0.003, -0.005 to 0.000; p = 0.022). Angiotensin-converting enzyme (ACE)/ACE2 and ACE were independent variables for final AIx@75 (B = 0.036, 0.005 to 0.066; p = 0.024) and PP (B = 0.010, 0.003 to 0.017; p = 0.01), respectively. There was no correlation between ΔAS and anthropometric changes nor with Δ of adipokines or inflammatory markers except high-sensitivity C-reactive protein (hs-CRP). Patients with PWV below median decreased PWV (mean, 95%CI = -0.18, -0.25 to -0.10; p < 0.001) and both AIx@75 and PP at 1-month, but not those with PWV above median. In conclusion, there is an improvement in AS 1-month post-BS that correlates with ΔBP and Δrenin-angiotensin-aldosterone components. The benefit is reduced in those with higher PWV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Matrix Metalloproteinases in Diabetic Kidney Disease

  • García Fernández, Nuria|||0000-0003-1082-0806
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Mora Gutiérrez, José María|||0000-0001-8537-5394
  • Vergara, Ander|||0000-0003-1926-0147
  • Orbe, Josune|||0000-0001-6300-7670
  • Soler, María José|||0000-0003-3621-0766
Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumulation causing thickening of the glomerular and tubular basement membranes, mesangial expansion, sclerosis, and tubulointerstitial fibrosis. The matrix metalloproteases (MMPs) family are composed of zinc-dependent enzymes involved in the degradation and hydrolysis of ECM components. Several MMPs are expressed in the kidney; nephron compartments, vasculature and connective tissue. Given their important role in DKD, several studies have been performed in patients with DKD proposing that the measurement of their activity in serum or in urine may become in the future markers of early DKD. Studies from diabetic nephropathy experimental models suggest that a balance between MMPs levels and their inhibitors is needed to maintain renal homeostasis. This review focuses in the importance of the MMPs within the kidney and their modifications at the circulation, kidney and urine in patients with DKD. We also cover the most important studies performed in experimental models of diabetes in terms of MMPs levels, renal expression and its down-regulation effect.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria

  • Moreso, Francesc|||0000-0002-7267-3963
  • Sellarès, Joana
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
The clinical significance of renal transplant biopsies displaying borderline changes suspicious for T-cell mediated rejection (TCMR) or interstitial fibrosis and tubular atrophy (IFTA) with interstitial inflammation has not been well defined. Molecular profiling to evaluate renal transplant biopsies using microarrays has been shown to be an objective measurement that adds precision to conventional histology. We review the contribution of transcriptomic analysis in surveillance and indication biopsies with borderline changes and IFTA associated with variable degrees of inflammation. Transcriptome analysis applied to biopsies with borderline changes allows to distinguish patients with rejection from those in whom mild inflammation mainly represents a response to injury. Biopsies with IFTA and inflammation occurring in unscarred tissue display a molecular pattern similar to TCMR while biopsies with IFTA and inflammation in scarred tissue, apart from T-cell activation, also express B cell, immunoglobulin and mast cell-related genes. Additionally, patients at risk for IFTA progression can be identified by genes mainly reflecting fibroblast dysregulation and immune activation. At present, it is not well established whether the expression of rejection gene transcripts in patients with fibrosis and inflammation is the consequence of an alloimmune response, tissue damage or a combination of both.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GLP-1 Receptor Agonists and Diabetic Kidney Disease, A Call of Attention to Nephrologists

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Soler, María José|||0000-0003-3621-0766
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • García-Carro, Clara|||0000-0002-5130-603X
  • Puchades, María Jesús
  • D'Marco, Luis|||0000-0003-0148-891X
  • Martínez Castelao, Alberto|||0000-0003-3889-5578
  • Fernández-Fernández, Beatriz
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Górriz-Zambrano, Carmen
  • Navarro Pérez, Jorge|||0000-0001-7414-7126
  • Gorgojo Martínez, Juan José|||0000-0002-8679-0968
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin-angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Potential of Extracellular Vesicle-Associated TSG-6 from Adipose Mesenchymal Stromal Cells in Traumatic Brain Injury

  • Roura, Santiago|||0000-0003-4063-9661
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Munizaga-Larroudé, Micaela
  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Multipotent mesenchymal stromal cells (MSC) represent a promising strategy for a variety of medical applications. Although only a limited number of MSC engraft and survive after in vivo cellular infusion, MSC have shown beneficial effects on immunomodulation and tissue repair. This indicates that the contribution of MSC exists in paracrine signaling, rather than a cell-contact effect of MSC. In this review, we focus on current knowledge about tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) and mechanisms based on extracellular vesicles (EV) that govern long-lasting immunosuppressive and regenerative activity of MSC. In this context, in particular, we discuss the very robust set of findings by Jha and colleagues, and the opportunity to potentially extend their research focus on EV isolated in concentrated conditioned media (CCM) from adipose tissue derived MSC (ASC). Particularly, the authors showed that ASC-CCM mitigated visual deficits after mild traumatic brain injury in mice. TSG-6 knockdown ASC were, then, used to generate TSG-6-depleted CCM that were not able to replicate the alleviation of abnormalities in injured animals. In light of the presented results, we envision that the infusion of much distilled ASC-CCM could enhance the alleviation of visual abnormalities. In terms of EV research, the advantages of using size-exclusion chromatography are also highlighted because of the enrichment of purer and well-defined EV preparations. Taken together, this could further delineate and boost the benefit of using MSC-based regenerative therapies in the context of forthcoming clinical research testing in diseases that disrupt immune system homeostasis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors

  • Carreras-Planella, Laura|||0000-0003-3512-0849
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Taco, Omar|||0000-0001-9081-5665
  • Cañas, Laura
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Lauzurica, Ricardo|||0000-0002-8051-5199
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

  • García-Carro, Clara|||0000-0002-5130-603X
  • Vergara, Ander|||0000-0003-1926-0147
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Espinel Garuz, Eugenia
  • Seron, Daniel|||0000-0003-2054-653X
  • Soler, María José|||0000-0003-3621-0766
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rituximab, plasma exchange and immunoglobulins, an ineffective treatment for chronic active antibody-mediated rejection

  • Piñeiro, Gastón Julio|||0000-0003-3806-4731
  • De Sousa-Amorim, Erika
  • Solé, Manel|||0000-0003-0131-272X
  • Ríos, José|||0000-0002-0716-8784
  • Lozano, Miquel|||0000-0003-2593-833X
  • Cofan, Frederic|||0000-0003-4163-9620
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Cucchiari, David|||0000-0002-7594-1070
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Cid, Joan|||0000-0001-5445-4508
  • Palou, Eduard|||0000-0003-1544-1485
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Oppenheimer, Federico|||0000-0002-1117-831X
  • Rovira, Jordi|||0000-0001-8737-5005
  • Diekmann, Fritz|||0000-0001-6199-3016
Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a cohort of patients with transplant glomerulopathy (TG) that met criteria of active cABMR, according to BANFF'17 classification, was identified. We identified 62 patients with active c-aABMR and TG (cg ≥ 1). Twenty-three patients were treated with the combination therapy and, 39 patients did not receive treatment and were considered the control group. There were no significant differences in the graft survival between the two groups. The number of graft losses at 12 and 24 months and the decline of eGFR were not different and independent of the treatment. A decrease of eGFR≥13 ml/min between 6 months before and c-aABMR diagnosis, was an independent risk factor for graft loss at 24 months (OR = 5; P = 0.01). Infections that required hospitalization during the first year after c-aABMR diagnosis were significantly more frequent in treated patients (OR = 4.22; P = 0.013), with a ratio infection/patient-year of 0.65 and 0.20 respectively. Treatment with rituximab, PE, and IVIG in kidney transplants with c-aABMR did not improve graft survival and was associated with a significant increase in severe infectious complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Arroyo, David|||0000-0003-4652-0311
  • D'Marco, Luis|||0000-0003-0148-891X
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Tomás, Patricia
  • Puchades, María Jesús
  • Panizo, Nayara|||0000-0002-1329-2976
  • Pantoja, Jonay
  • Montomoli, Marco|||0000-0003-1412-6352
  • Llisterri, José Luis
  • Pallarés Carratalá, Vicente|||0000-0002-2985-6078
  • Valdivielso, José Manuel|||0000-0003-1343-0184
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. We evaluated 2445 CKD patients (2010-2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221-0.808, p = 0.009). ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. The online version contains supplementary material available at 10.1186/s12882-021-02313-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

  • Hernández, Domingo
  • Vázquez, Teresa
  • Alonso-Titos, Juana
  • León, Myriam
  • Caballero, Abelardo
  • Cobo, María Angeles
  • Sola, Eugenia|||0000-0002-9462-3342
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Ruiz-Esteban, Pedro
  • Cruzado, Josep María
  • Sellarés, Joana
  • Moreso, Francesc|||0000-0002-7267-3963
  • Manonelles, Anna|||0000-0003-2456-388X
  • Torio, Alberto
  • Cabello, Mercedes
  • Delgado-Burgos, Juan
  • Casas, Cristina
  • Gutiérrez, Elena
  • Jironda, Cristina
  • Kanter, Julia
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring Renal Changes after Bariatric Surgery in Patients with Severe Obesity

  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Vázquez, Susana
  • Soler, María José|||0000-0003-3621-0766
  • Galceran, Isabel
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • Benaiges, David|||0000-0001-5411-364X
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Riera Oliva, Marta|||0000-0003-4362-7965
Obesity-related hyperfiltration leads to an increased glomerular filtration rate (GFR) and hyperalbuminuria. These changes are reversible after bariatric surgery (BS). We aimed to explore obesity-related renal changes post-BS and to seek potential mechanisms. Sixty-two individuals with severe obesity were prospectively examined before and 3, 6 and 12 months post-BS. Anthropometric and laboratory data, 24 h-blood pressure, renin-angiotensin-aldosterone system (RAS) components, adipokines and inflammatory markers were determined. Both estimated GFR (eGFR) and albuminuria decreased from the baseline at all follow-up times (p -for-trend <0.001 for both). There was a median (IQR) of 30.5% (26.2-34.4) reduction in body weight. Plasma glucose, glycosylated hemoglobin, fasting insulin and HOMA-index decreased at 3, 6 and 12 months of follow-up (p -for-trend <0.001 for all). The plasma aldosterone concentration (median (IQR)) also decreased at 12 months (from 87.8 ng/dL (56.8; 154) to 65.4 (56.8; 84.6), p = 0.003). Both leptin and hs-CRP decreased (p < 0.001) and adiponectine levels increased at 12 months post-BS (p = 0.017). Linear mixed-models showed that body weight (coef. 0.62, 95% CI: 0.32 to 0.93, p < 0.001) and plasma aldosterone (coef. -0.07, 95% CI: -0.13 to -0.02, p = 0.005) were the independent variables for changes in eGFR. Conversely, glycosylated hemoglobin was the only independent variable for changes in albuminuria (coef. 0.24, 95% CI: 0.06 to 0.42, p = 0.009). In conclusion, body weight and aldosterone are the main factors that mediate eGFR changes in obesity and BS, while albuminuria is associated with glucose homeostasis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The 2019 and 2021 International Workshops on Alport Syndrome

  • Daga, Sergio
  • Ding, Jie
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220
In 1927 Arthur Cecil Alport, a South African physician, described a British family with an inherited form of kidney disease that affected males more severely than females and was sometimes associated with hearing loss. In 1961, the eponymous name Alport syndrome was adopted. In the late twentieth century three genes responsible for the disease were discovered: COL4A3, COL4A4, and COL4A5 encoding for the α3, α4, α5 polypeptide chains of type IV collagen, respectively. These chains assemble to form heterotrimers of type IV collagen in the glomerular basement membrane. Scientists, clinicians, patient representatives and their families, and pharma companies attended the 2019 International Workshop on Alport Syndrome, held in Siena, Italy, from October 22 to 26, and the 2021 online Workshop from November 30 to December 4. The main topics included: disease re-naming, acknowledging the need to identify an appropriate term able to reflect considerable clinical variability; a strategy for increasing the molecular diagnostic rate; genotype-phenotype correlation from monogenic to digenic forms; new therapeutics and new therapeutic approaches; and gene therapy using gene editing. The exceptional collaborative climate that was established in the magical medieval setting of Siena continued in the online workshop of 2021. Conditions were established for collaborations between leading experts in the sector, including patients and drug companies, with the aim of identifying a cure for Alport syndrome.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment of early borderline lesions in low immunological risk kidney transplant patients, a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

  • Hernández, Domingo
  • Vázquez Sánchez, Teresa
  • Sola, Eugenia|||0000-0002-9462-3342
  • Lopez, Veronica
  • Ruiz-Esteban, Pedro
  • Caballero, Abelardo
  • Salido, Eduardo
  • León, Myriam
  • Rodriguez, Aurelio
  • Serra, Núria|||0000-0001-7926-2625
  • Rodríguez, Consuelo
  • Facundo, Carme|||0000-0003-1254-5553
  • Perello, Manel
  • Silva, Irene|||0000-0002-2723-1031
  • Marrero-Miranda, Domingo
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Guirado, Luis|||0000-0001-5119-3912
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of treating these BL on renal function and graft histology. Furthermore, these studies have only used bolus steroids, which may be insufficient to slow the progression of these lesions. Klotho, a transmembrane protein produced mainly in the kidney with antifibrotic properties, plays a crucial role in the senescence-inflammation binomial of kidney tissue. Systemic and local inflammation decrease renal tissue expression and soluble levels of α-klotho. It is therefore important to determine whether treatment of BL prevents a decrease in α-klotho levels, progression of IFTA, and loss of kidney function. The TRAINING study will randomize 80 patients with low immunological risk who will receive their first KT. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with polyclonal rabbit antithymocyte globulin (Grafalon®) (6 mg/kg/day) prevents or decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT, as well as to analyze whether treatment of BL with Grafalon® can modify the expression and levels of klotho, as well as the pro-inflammatory cytokines that regulate its expression. This phase IV investigator-driven, randomized, placebo-controlled clinical trial will examine the efficacy and safety of Grafalon® treatment in low-immunological-risk KT patients with early BL. : NCT04936282. Registered June 23, 2021, . Protocol Version 2 of 21 January 2022. Sponsor: Canary Isles Institute for Health Research Foundation, Canary Isles (FIISC). mgomez@fciisc.org.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

  • Naranjo, Javier|||0000-0002-7004-6122
  • Furlano, Monica|||0000-0003-1025-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Pybus, Marc|||0000-0002-6195-5738
  • Ejarque, Laia
  • Cordoba, Christian|||0000-0003-4534-2760
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. Methods: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C-1E was assessed. Results: A total of 118 patients were MC 1C-1E. The algorithm developed by the European Renal Association-European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C-1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients

  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Perpiñan, Héctor
  • Amigó, Núria|||0000-0002-0116-9145
  • Castro Boque, Eva
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Fernandez, Elvira
  • Valdivielso, José Manuel|||0000-0003-1343-0184
Background: Chronic kidney disease (CKD) patients have a high burden of atheromatous cardiovascular disease (ASCVD) not fully explained by traditional lipid parameters. Lipoprotein composition and subclass particle number information could improve ASCVD risk assessment. The objective of this study is to investigate the association of advanced lipoprotein parameters with the risk of atheromatosis in a subpopulation of the NEFRONA study. Methods: This was a cross-sectional study in 395 non-diabetic individuals (209 CKD and 186 non-diabetic and non-CKD) without statin therapy. Vascular ultrasound examination assessing 10 territories was combined with advanced lipoprotein testing performed by nuclear magnetic resonance spectroscopy. Logistic regression was used to estimate adjusted odds ratios (ORs) per 1 standard deviation increment. Results: Atheromatosis was more prevalent in CKD patients (33.9% versus 64.6%). After adjusting for age, gender, smoking habit and CKD stage, the amount of triglycerides (TGs) within low-density lipoprotein (LDL) lipoproteins was independently and positively associated with atheromatosis [OR 1.33; 95% confidence interval (CI) 1.03-1.74; P = 0.03]. Similarly, total and medium LDL particles (LDL-Ps) showed a positive association (OR 1.29; 95% CI 1.00-1.68; P = 0.05 and OR 1.34; 95% CI 1.04-1.75; P = 0.03, respectively). TG-loaded medium LDL-Ps were higher in CKD patients compared with controls and showed an adjusted OR of 1.40 (95% CI 1.09-1.82; P = 0.01) in non-diabetic patients (CKD and non-CKD individuals). In contrast, non-diabetic CKD patients showed a similar coefficient but the significance was lost (OR 1.2; 95% CI 0.8-1.7; P = 0.359). Conclusions: Non-diabetic CKD patients showed a higher amount of TG-loaded medium LDL-Ps compared with controls. These particles were independently associated with atheromatosis in non-diabetic patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

  • Buxeda, Anna|||0000-0001-7305-3259
  • Arias Cabrales, Carlos E.|||0000-0002-1729-8152
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Cacho, Judit
  • Cabello Pelegrín, Sheila|||0000-0001-9319-6935
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Aladrén Regidor, Mª José|||0000-0002-1043-9979
  • Galeano Alvarez, Cristina|||0000-0003-2785-8886
  • Lorenzo, Iinmaculada
  • Mazuecos, Auxiliadora|||0000-0002-5860-2309
  • Saura, Isabel María
  • Franco, Antonio
  • Ruiz-Fuentes, María del Carmen
  • Sánchez-Cámara, Luis Alberto
  • Siverio, Orlando
  • Martin, María Luisa
  • González-García, Elena
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Martin-Moreno, Paloma Leticia
  • Moina, Iñigo
  • Moral Berrio, Esperanza
  • Moreso, Francesc|||0000-0002-7267-3963
  • Portolés, José María
  • Santana-Estupiñán, Raquel
  • Zárraga, Sofía
  • Canal Girol, Cristina|||0000-0003-2556-872X
  • Sánchez-Álvarez, Emilio
  • Pascual, Julio|||0000-0002-4735-7838
  • Crespo, Marta|||0000-0001-6992-6379
Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recommendations for living donor kidney transplantation Recomendaciones para el trasplante renal de donante vivo

  • Frutos, Migeul Ángel
  • Crespo, Marta|||0000-0001-6992-6379
  • Valentín, María de la Oliva
  • Alonso-Melgar, Ángel
  • Alonso, Juana
  • Fernández, Constantino
  • García-Erauzkin, Gorka
  • González, Esther
  • González-Rinne, Ana M.
  • Guirado, Luis|||0000-0001-5119-3912
  • Gutiérrez Dalmau, Álex
  • Huguet Perez, Jordi
  • López del Moral, José Luis
  • Musquera, Mireia
  • Paredes, David
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Van-der Hofstadt, Carlos J.
  • Alcaraz, Antonio|||0000-0003-2612-5250
  • Alonso-Hernández, Ángel
  • Alonso, Manuel
  • Bernabeu, Purificación
  • Bernal Blanco, Gabriel
  • Breda, Alberto|||0000-0002-7842-9048
  • Cabello, Mercedes
  • Caro-Oleas, José Luis
  • Cid, Joan|||0000-0001-5445-4508
  • Diekmann, Fritz|||0000-0001-6199-3016
  • Espinosa, Laura
  • Facundo, Carme|||0000-0003-1254-5553
  • García, Marta|||0000-0001-5155-4730
  • Gil-Vernet, Salvador
  • Lozano, Miquel|||0000-0003-2593-833X
  • Mahillo, Beatriz
  • Martínez, María José
  • Miranda Serrano, Blanca
  • Oppenheimer, Federico|||0000-0002-1117-831X
  • Palou, Eduard|||0000-0003-1544-1485
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Peri, Lluis
  • Rodríguez Faba, Óscar|||0000-0001-6668-4423
  • Santiago, Carlos
  • Tabernero, Guadalupe
  • Hernández, Domingo
  • Domínguez-Gil, Beatriz|||0000-0002-5695-8993
  • Pascual, Julio|||0000-0002-4735-7838
This Guide for Living Donor Kidney Transplantation (LDKT) has been prepared with the sponsorship of the Spanish Society of Nephrology (SEN), the Spanish Transplant Society (SET), and the Spanish National Transplant Organization (ONT). It updates evidence to offer the best chronic renal failure treatment when a potential living donor is available. The core aim of this Guide is to supply clinicians who evaluate living donors and transplant recipients with the best decision-making tools, to optimise their outcomes. Moreover, the role of living donors in the current KT context should recover the level of importance it had until recently. To this end the new forms of incompatible HLA and/or ABO donation, as well as the paired donation which is possible in several hospitals with experience in LDKT, offer additional ways to treat renal patients with an incompatible donor. Good results in terms of patient and graft survival have expanded the range of circumstances under which living renal donors are accepted. Older donors are now accepted, as are others with factors that affect the decision, such as a borderline clinical history or alterations, which when evaluated may lead to an additional number of transplantations. This Guide does not forget that LDKT may lead to risk for the donor. Pre-donation evaluation has to centre on the problems which may arise over the short or long-term, and these have to be described to the potential donor so that they are able take them into account. Experience over recent years has led to progress in risk analysis, to protect donors' health. This aspect always has to be taken into account by LDKT programmes when evaluating potential donors. Finally, this Guide has been designed to aid decision-making, with recommendations and suggestions when uncertainties arise in pre-donation studies. Its overarching aim is to ensure that informed consent is based on high quality studies and information supplied to donors and recipients, offering the strongest possible guarantees.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease in young adults

  • Martínez, Víctor
  • Furlano, Monica|||0000-0003-1025-3901
  • Sans, Laia
  • Pulido, Lissett
  • García, Rebeca|||0000-0003-0649-2766
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Sánchez-Rodríguez, Jinny
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Castro-Alonso, Cristina|||0000-0002-8363-1953
  • Fernández-Fresnedo, Gema
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Valenzuela, María Pau
  • Naranjo, Javier|||0000-0002-7004-6122
  • Martín Alemany, Nàdia|||0000-0002-4370-7562
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • González-Rodríguez, Juan David|||0000-0002-8863-2007
  • Panizo, Nayara|||0000-0002-1329-2976
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Fernández, Loreto
  • López, María Teresa
  • Dall'Anese, Cecilia
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Torra Balcells, Roser|||0000-0001-8714-2332
The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. Family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR) and imaging tests were examined in 346 young adults (18-30 years old) out of 2521 patients in the Spanish ADPKD registry (REPQRAD). A literature review searched for reports on hypertension in series with more than 50 young (age <30 years) ADPKD patients. The mean age of this young adult cohort was 25.24 (SD 3.72) years. The mean age at diagnosis of hypertension was 21.15 (SD 4.62) years, while in the overall REPQRAD population was aged 37.6 years. The prevalence of hypertension was 28.03% and increased with age (18-24 years, 16.8%; 25-30 years, 36.8%). Although prevalence was lower in women than in men, the age at onset of hypertension (21 years) was similar in both sexes. Mean eGFR was 108 (SD 21) mL/min/1.73 m 2, 38.0% had liver cysts and 3.45% of those studied had intracranial aneurysms. In multivariate analyses, hematuria episodes and kidney length were independent predictors of hypertension (area under the curve 0.75). The prevalence of hypertension in 22 pediatric cohorts was 20%-40%, but no literature reports on hypertension in young ADPKD adults were found. Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment of young adults at risk of ADPKD that allows early diagnosis and treatment of hypertension.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal

  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Vázquez, Teresa
  • Alonso-Titos, Juana
  • Cabello, Mercedes
  • Alonso Hernández, Ángel
  • Beneyto, Isabel|||0000-0002-8433-3448
  • Crespo, Marta|||0000-0001-6992-6379
  • Díaz-Corte, Carmen
  • Franco, Antonio
  • González-Roncero, Francisco
  • Gutiérrez, Elena
  • Guirado, Luis|||0000-0001-5119-3912
  • Jiménez Martín, Carlos
  • Jironda, Cristina
  • Lauzurica, Ricardo|||0000-0002-8051-5199
  • Llorente, Santiago
  • Mazuecos, Auxiliadora|||0000-0002-5860-2309
  • Paul, Javier
  • Rodríguez-Benot, Alberto
  • Ruiz, Juan Carlos|||0000-0002-7904-8730
  • Sánchez Fructuoso, Ana Isabel|||0000-0001-7017-9729
  • Sola, Eugenia|||0000-0002-9462-3342
  • Torregrosa, Vicente
  • Zárraga, Sofía
  • Hernández, Domingo
The SARS-CoV-2 (Covid-19) coronavirus pandemic is evolving very quickly and means a special risk for both immunosuppressed and comorbid patients. Knowledge about this growing infection is also increasing although many uncertainties remain, especially in the kidney transplant population. This manuscript presents a proposal for action with general and specific recommendations to protect and prevent infection in this vulnerable population such as kidney transplant recipients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

  • Nuñez, Estefania|||0000-0002-0876-1264
  • Fuster, Valentín
  • Gómez-Serrano, María
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Fernández-Alvira, Juan Miguel
  • Martínez-López, Diego
  • Rodríguez, José Manuel
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Calvo, Enrique
  • Alfayate, Alvaro
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Fernández-Friera, Leticia
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Mendiguren, José María
  • Sánchez-Cabo, Fátima|||0000-0003-1881-1664
  • Sanz Salvo, Javier
  • Ordovás, José María
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • García-Ruiz, José Manuel
  • Ibañez, Borja|||0000-0002-5036-254X
  • Lara-Pezzi, Enrique
  • Fernández-Ortiz, Antonio
  • Martín-Ventura, José Luis
  • Vázquez, Jesús|||0000-0003-1461-5092
Background: Imaging of subclinical atherosclerosis improves cardiovascular risk prediction on top of traditional risk factors. However, cardiovascular imaging is not universally available. This work aims to identify circulating proteins that could predict subclinical atherosclerosis. Methods: Hypothesis-free proteomics was used to analyze plasma from 444 subjects from PESA cohort study (222 with extensive atherosclerosis on imaging, and 222 matched controls) at two timepoints (three years apart) for discovery, and from 350 subjects from AWHS cohort study (175 subjects with extensive atherosclerosis on imaging and 175 matched controls) for external validation. A selected three-protein panel was further validated by immunoturbidimetry in the AWHS population and in 2999 subjects from ILERVAS cohort study. Findings: PIGR, IGHA2, APOA, HPT and HEP2 were associated with subclinical atherosclerosis independently from traditional risk factors at both timepoints in the discovery and validation cohorts. Multivariate analysis rendered a potential three-protein biomarker panel, including IGHA2, APOA and HPT. Immunoturbidimetry confirmed the independent associations of these three proteins with subclinical atherosclerosis in AWHS and ILERVAS. A machine-learning model with these three proteins was able to predict subclinical atherosclerosis in ILERVAS (AUC [95%CI]:0.73 [0.70-0.74], p < 1 × 10), and also in the subpopulation of individuals with low cardiovascular risk according to FHS 10-year score (0.71 [0.69-0.73], p < 1 × 10). Interpretation: Plasma levels of IGHA2, APOA and HPT are associated with subclinical atherosclerosis independently of traditional risk factors and offers potential to predict this disease. The panel could improve primary prevention strategies in areas where imaging is not available.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RICORS2040, The need for collaborative research in chronic kidney disease

  • Ortiz, Alberto|||0000-0002-9805-9523
  • Roger, Marta
  • Martínez Jiménez, Victor
  • Rodriguez Perez, Jose Carlos
  • Furlano, Monica|||0000-0003-1025-3901
  • Sans Atxer, Laia
  • Gallego Zurro, Daniel
  • Romeo Casabona, Carlos María
  • Gómez Gómez, Clemente
  • Pérez Bermúdez, Pilar
  • Arellano Armisen, Manuel
  • Albadalejo López, Santiago
  • Gutiérrez Porras, Inmaculada
  • Gómez Ruiz, Josefa
  • Martin Orgaz, José Manuel
  • Moreno Barón, Marta
  • de Sequera, Patricia|||0000-0001-7705-9228
  • Arriba, Gabriel de|||0000-0001-6626-623X
  • Quiroga, Borja|||0000-0001-5730-1929
  • Fernández Fresnedo, Gema
  • Soriano Cabrera, Sagrario|||0000-0002-0530-3022
  • Pérez Contreras, Javier
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Mazuecos, Auxiliadora|||0000-0002-5860-2309
  • Rodriguez, Mariano|||0000-0002-9380-6614
  • Sánchez Álvarez, J.Emilio
  • Soler, María José|||0000-0003-3621-0766
  • Gorostidi Pérez, Manuel
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Hernández Marrero, Domingo
  • Fondevila, Constantino|||0000-0002-6161-6824
  • Miñambres García, Eduardo|||0000-0002-0466-044X
  • G. Cosío, M. Dolores|||0000-0002-9330-9896
  • Torres, Armando|||0000-0003-1121-5173
  • Muñoz-Bellvis, Luis|||0000-0002-7809-5201
  • Berenguer, Marina|||0000-0001-9246-4264
  • Barrera Gómez, Manuel
  • Cifrián Martínez, José Manuel
  • Cruzado Garrit, Josep María
  • San Juan Garrido, Rafael
  • Javier, Briceño Delgado
  • Bodro, Marta|||0000-0002-0520-8279
  • Valentín Muñoz, María O.
  • Pérez Villares, José Miguel
  • Salvatierra Velázquez, Ángel
  • Almenar Bonet, Luis|||0000-0002-7710-361X
  • Gómez-Bravo, Miguel A.|||0000-0002-5155-3508
  • Moreso Mateos, Francesc J.
  • Muro, Manuel|||0000-0001-9987-0994
  • Pons Miñano, José A.
  • Andrés Belmonte, Amado
  • Solé Jover, Amparo
  • Casanova Rituerto, Daniel
  • Pardo Sánchez, Fernando
  • Arenas Jimenez, Maria Dolores|||0000-0003-3470-3137
  • Martín Hernández, Roberto
  • Miranda Serrano, Blanca
  • Sanz, Ana B.
  • Ramos, Adrián M.
  • Córdoba-David, Gina
  • García-Jiménez, Jorge
  • Fontecha-Barriuso, Miguel
  • Guerrero-Mauvecin, Juan
  • Lopez-Díaz, Ana M.
  • Sánchez Niño, María Dolores
  • Valiño-Rivas, Lara
  • Cuarental, Leticia
  • Ribagorda, Marta
  • Pintor-Chocano, Aranzazu
  • Favero, Chiara
  • Alvarez-Llamas, Gloria
  • Martín Cleary, Catalina
  • Fernández-Fernández, Beatriz
  • Pérez-Gómez, María Vanessa
  • Alegre De Montaner, Emma Raquel
  • Fernández Prado, Raúl
  • Rojas Rivera, Jorge
  • Ramos Verde, Ana María
  • Luis-Lima, Sergio|||0000-0003-3540-8252
  • Sánchez-Rodríguez, Jinny
  • Pizarro Sánchez, Soledad
  • Ruiz Ortega, Marta
  • González Parra, Emilio
  • Rayego Mateos, Sandra
  • Cannata Ortiz, Pablo Javier
  • Márquez Expósito, Laura
  • Tejera-Muñoz, Antonio
  • Marchant, Vanessa
  • Tejedor-Santamaria, Lucia
  • Alique Agilar, Matilde
  • Diekmann, Fritz|||0000-0001-6199-3016
  • Bayés Genís, Beatriu|||0000-0003-1233-7631
  • Oppenheimer Salinas, Federico
  • Ramírez Bajo, María José
  • Banon-Maneus, Elisenda
  • Arias Guillén, Marta|||0000-0001-8023-2589
  • Rovira Juárez, Jordi
  • Lazo-Rodriguez, Marta
  • Revuelta Vicente, Ignacio
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Abreu Aguiar, Pedro Ventura
  • Xipell Font, Marc
  • Molina Andujar, Alicia
  • Cucchiari, David|||0000-0002-7594-1070
  • Montagud Marrah, Enrique
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Piñeiro, Gastón Julio|||0000-0003-3806-4731
  • Martínez Salgado, Carlos
  • Morales Martín, Ana I.
  • López Hernández, Francisco J.
  • Balboa, Nélida Eleno
  • Prieto Vicente, Marta
  • Fuentes Calvo, Isabel
  • Ramudo González, Laura
  • Vicente Vicente, Laura
  • Sancho Martínez, Sandra M.
  • Casanova Paso, Alfredo G.
  • Pescador Garriel, Moisés
  • Vaquero López, Juan José
  • Cuadro Palacios, Ana María
  • Sucunza Saénz, David
  • Aceña, José Luis|||0000-0002-1777-8199
  • Garcia, Patricia
  • Fernández Rodríguez, Manuel A.
  • Domingo Galán, Alberto
  • Merino Marcos, Estíbaliz
  • Carreras Pérez-Aradros, Javier
  • Manzano San José, Rubén
  • Maqueda Zelaya, Francisco u Universidad de Alcalá
  • Sans Panadés, Ester
  • González Molina, Álvaro
  • Atarejos Salido, Julia|||0000-0002-2871-8597
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Guirado, Luis|||0000-0001-5119-3912
  • Canal Girol, Cristina|||0000-0003-2556-872X
  • Arce, Yolanda
  • Pybus, Marc|||0000-0002-6195-5738
  • Ejarque, Laia
  • Serra, Núria|||0000-0001-7926-2625
  • Facundo, Carme|||0000-0003-1254-5553
  • Silva, Irene|||0000-0002-2723-1031
  • Lamas Pelaez, Santiago
  • Rey Serra, Carlos
  • Castillo Torres, Carolina
  • Tituaña, Jessica Paola|||0000-0002-3337-8363
  • Herrero Lahuerta, José Ignacio
  • Miguel Herranz, Verónica
  • Martín Malo, Alejandro|||0000-0001-8418-4617
  • Muñoz Castañeda, Juan R.|||0000-0002-9341-0724
  • Rodríguez Ortiz, María Encarnación|||0000-0002-3696-582X
  • Martínez Moreno, Julio Manuel|||0000-0002-1945-5078
  • Raya Bermúdez, Ana Isabel
  • Santamaría Olmo, Rafael
  • Guerrero Pavón, Fátima|||0000-0003-1306-0574
  • Moyano Peregrin, Cayetana
  • Aguilera Tejero, Escolástico|||0000-0002-3357-3142
  • López Villalba, Ignacio
  • Carmona Muñoz, Andrés
  • Pendon-Ruiz de Mier, María Victoria|||0000-0002-7647-9391
  • Pineda Martos, Carmen María|||0000-0002-3664-8699
  • López Baltanás, Rodrigo|||0000-0003-2598-7182
  • Rodelo Haad, Cristian|||0000-0002-8139-3840
  • Lauzuricao Valdemoros, Ricardo
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Cañas, Laura
  • Troya Saborido, María Isabel
  • Soler Majoral, Jordi|||0000-0001-6693-4859
  • López Martínez, Marina
  • Rodrigo Calabia, Emilio|||0000-0002-2845-5272
  • Ruíz San Millán, Juan Carlos
  • López-Hoyos, Marcos|||0000-0003-0562-427X
  • Benito-Hernández, Adalberto|||0000-0002-8733-1878
  • San Segundo, David|||0000-0001-5745-9072
  • Valero, Rosalía
  • Coto García, Eliécer|||0000-0002-8649-9150
  • Gómez de Ona, Juan
  • Cuesta-Llavona, Elias|||0000-0002-0924-0962
  • Santos Rodríguez, Fernando
  • Lorca Gutiérrez, Rebeca
  • Gil Peña, Helena|||0000-0002-8790-1391
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Sola, Eugenia|||0000-0002-9462-3342
  • Cabello, Mercedes
  • Caballero, Abelardo
  • León, Myriam
  • Ruíz, Pedro
  • Alonso, Juana
  • Navarro-González, Juan
  • Mora-Fernández, Carmen|||0000-0003-1570-6332
  • Donate-Correa, Javier|||0000-0001-7389-7347
  • Martín-Nuñez, Ernesto|||0000-0003-0341-0956
  • Pérez Delgado, Nayra|||0000-0001-5255-859X
  • Gigarrán-Guldris, Secundino|||0000-0001-5624-2605
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Martínez Castelao, Alberto|||0000-0003-3889-5578
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Martínez, Cristina|||0000-0002-9368-1356
  • Bozic Stanojevic, Milica|||0000-0002-6064-1446
  • Castro Boque, Eva
  • Sans Rosell, María Nuria
  • De Lamo, Virtudes María
  • Díaz Tocados, Juan Miguel|||0000-0001-5192-5212
  • García Carrasco, Alicia|||0000-0002-2590-9195
  • Bermúdez López, Marcelino
  • Caus Enriquez, Maite
  • Martínez Bardaji, Ana
  • Dolade Masot, Nuria|||0000-0003-2311-2825
  • Pérez Gómez, Aurora|||0000-0003-3456-6902
  • Eritja Sanjuan, Auria|||0000-0002-4746-8538
  • Osuna Ortega, Antonio
  • Wangensteen Fuentes, Rosemary
  • De Gracia Guindo, María del Carmen
  • Ruíz Fuentes, Maria Del Carmen
  • O'Valle Ravassa, Francisco
  • Caba Molina, Mercedes|||0000-0001-8259-7346
  • Ramírez Tortosa, César Luis|||0000-0002-3302-707X
  • García Del Moral Garrido, Raimundo
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Moreso, Francesc|||0000-0002-7267-3963
  • Meneghini, Maria|||0000-0001-7307-923X
  • Sellares, Joana|||0000-0002-0394-8011
  • Torres Betsabé, Irina
  • López Larrea, Carlos
  • Suárez Álvarez, Beatriz
  • Díaz-Corte, Carmen
  • Rodrigues-Diez, Raúl R.
  • López Vázquez, Antonio
  • González Rodríguez, Segundo
  • Vidal Castiñeira, José Ramón
  • Martín Martín, Cristina
  • Saiz Álvarez, María Laura
  • Corte Iglesias, Viviana
  • Martínez Borra, Jesús
  • Bajo Rubio, Maria Auxiliadora
  • Del Peso Gilsanz, Gloria
  • López Cabrera, Manuel
  • Jiménez, José Antonio
  • Ossorio González, Marta
  • Costero González, Olga
  • González García, María Elena
  • Jiménez Martín, Carlos
  • Sandoval Correa, Pilar
  • Alfonso Ramos, Sara
  • López Oliva, María Ovidia|||0000-0003-3503-3518
  • Rivas, Begoña|||0000-0002-5886-9943
  • Vega Cabrera, Cristina
  • González Mateo, Guadalupe Tirma|||0000-0002-8144-904X
  • Sánchez Villanueva, Rafael
  • Álvarez García, Laura
  • Cannata Andía, Jorge B.
  • Naves Díaz, Manuel
  • Fernandez-Martín, José Luis|||0000-0003-3455-1778
  • Carrillo-López, Natalia|||0000-0002-4227-4144
  • Panizo García, Sara
  • Alonso Montes, Cristina
  • Rodríguez García, Minerva
  • Lozano Martínez-Luengas, Iñigo
  • Sánchez-Álvarez, Emilio
  • Martínez Arias, Laura
  • Martín Carro, Beatriz
  • Martín Virgala, Julia
  • García González, Miguel
  • Lamas Barreiro, José María
  • Pérez Fontan, Miguel
  • Otero González, Alfonso
  • Cuiña Barja, Luz María
  • Sánchez Barreiro, Alejandro
  • Pazos Arias, Beatriz
  • Hernández, Ángel Alonso
  • Pardo Pérez, María
  • Calviño Varela, Jesús
  • Amigo, Jorge|||0000-0002-1362-2605
  • Díaz Rodríguez, Cándido
  • García Murias, María
  • Barcia De La Iglesia, Ana María
  • Bouza Piñeiro, Pablo
  • Gil González, Álvaro
  • Cordido Eijo, Adrian
  • Carrera Cachaza, Noe
  • Vizoso González, Marta
  • Lloberas Blanch, Núria
  • Solá Martínez, Ana Maria
  • Hueso Val, Miguel
  • Bordignon Draibe, Juliana
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Manonelles, Anna|||0000-0003-2456-388X
  • Montero Pérez, Núria
  • Fulladosa, Xavier|||0000-0003-1974-9874
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Barrios, Clara|||0000-0003-0492-4107
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Redondo Pachón, María Dolores
  • Cabrales, Carlos Arias
  • Buxeda Porras, Anna
  • Rodríguez García, Eva
  • Palau González, Vanesa
  • Llinàs Mallol, Laura|||0000-0003-4696-3331
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Rodríguez Puyol, Diego
  • Ruíz Torres, María Piedad
  • López Ongil, Susana
  • Calleros Basilio, Laura
  • Olmo Centenera, Gemma
  • Martínez De Miguel, Patricia
  • Fernández Rodríguez, Loreto
  • Bouarich Nadah, Hanane
  • Pérez Fernández, María
  • Ramírez Chamond, Manuel Rafael
  • Sequera Ortiz, Patricia
  • García Fernández, Nuria|||0000-0003-1082-0806
  • Benito Boillos, Alberto
  • Varo Cenarruzabeitia, Nerea
  • Fernández Seara, María Asunción
  • Díaz Dorronsoro, Inés
  • Martin Moreno, Paloma
  • Lavilla, Francisco Javier
  • Domingo Marrero, Miranda
  • Pastor Rodríguez Hernández, Aurelio
  • De Bonis Redondo, Eduardo
  • Porrini, Esteban
  • Cobo Caso, María de los Ángeles
  • Pérez Tamajón, María Lourdes
  • Rufino Hernández, Margarita
  • García Rebollo, María Sagrario
  • Delgado Mallen, Patricia
  • Álvarez González, Alejandra
  • González Rinne, Ana María
  • Rodríguez, Rosa Miquel
  • Estupiñan Torres, Sara
  • Álvarez Sosa, Diego
  • Zamora Rodríguez, Nayara
  • Fariña Hernández, Arminda
  • Rodríguez Gamboa, María José
  • García Bermejo, María Laura
  • Fernández Lucas, Milagros|||0000-0002-8019-3513
  • Escamilla Cabrera, Beatriz
  • Conde Moreno, Elisa
  • Salinas Muñoz, Laura
  • Serrano Huertas, Silvia
  • Serrano, Rodríguez, Esperanza Macarena|||0000-0003-3499-5926
  • Ramos Muñoz, Miren Edurne|||0000-0001-5388-0281
  • Crespo Toro, Lorena
  • Blanco Agudo, Carolina Pilar|||0000-0002-1213-2495
  • Galeano Alvarez, Cristina|||0000-0003-2785-8886
  • Portoles, José
  • Marqués, María
  • Rubio, Esther
  • Sánchez-Sobrino, Beatriz
  • García-Menéndez, Estefanya
  • Lázaro Fernández, Alberto
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Rodríguez Benítez, Patrocinio
  • González-Nicolás González, María Ángeles
  • López Gallardo, Meritxell
  • Fernández Juárez, Gema María
  • Gutiérrez Martínez, Eduardo
  • Praga Terente, Manuel
  • Tato Ribera, Ana
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Shabaka, Amir|||0000-0001-7039-4701
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Luna Huerta, Enrique
  • Gervasini Rodríguez, Guillermo|||0000-0002-0524-9767
  • Barroso Hernández, Sergio|||0000-0002-0588-2415
  • Mota Zamorano, Sonia
  • López Gómez, Juan Manuel
  • Hernández Gallego, Román|||0000-0002-5670-941X
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Direct-Acting Antivirals for the Treatment of Kidney Transplant Patients with Chronic Hepatitis C Virus Infection in Spain, A Long-Term Prospective Observational Study

  • González-Corvillo, Carmen
  • Beneyto, Isabel|||0000-0002-8433-3448
  • Sánchez Fructuoso, Ana Isabel|||0000-0001-7017-9729
  • Perelló, Manel|||0000-0003-1859-5279
  • Alonso Hernández, Ángel
  • Mazuecos, Auxiliadora|||0000-0002-5860-2309
  • Jiménez Martín, Carlos
  • Zárraga, Sofía
  • Paul, Javier
  • Lauzurica, Ricardo|||0000-0002-8051-5199
  • Hernández, Domingo
  • Guirado, Luis|||0000-0001-5119-3912
  • Franco, Antonio
  • Ruiz, Juan Carlos|||0000-0002-7904-8730
  • Llorente, Santiago
  • Crespo, Marta|||0000-0001-6992-6379
  • Rodríguez-Benot, Alberto
  • De Gracia Guindo, María del Carmen
  • Díaz-Corte, Carmen
  • Gentil, Miguel Ángel
Direct-Acting antivirals (DAA) allow effective and safe eradication of hepatitis C virus (HCV) in most patients. There are limited data on the long-Term effects of all-oral, interferon-free DAA combination therapies in kidney transplant (KT) patients infected with HCV. Here we evaluated the long-Term tolerability, efficacy, and safety of DAA combination therapies in KT patients with chronic HCV infection. Clinical data from KT patients treated with DAA were collected before, during, and after the treatment, including viral response, immunosuppression regimens, and kidney and liver function. Patients (N = 226) were mostly male (65.9%) aged 56.1 ± 10.9 years, with a median time from KT to initiation of DAA therapy of 12.7 years and HCV genotype 1b (64.6%). Most patients were treated with sofosbuvir-based therapies. Rapid virological response at 1 month was achieved by 89.4% of the patients and sustained virological response by week 12 by 98.1%. Liver function improved significantly after DAA treatment. Tacrolimus dosage increased 37% from the beginning of treatment (2.5 ± 1.7 mg/d) to 1 year after the start of DAA treatment (3.4 ± 1.9 mg/d, P < 0.001). Median follow-up was 37.0 months (interquartile range, 28.4-41.9) and death-censored graft survival was 91.1%. Adverse events resulting from DAA treatment, especially anemia, were reported for 31.0% of the patients. Chronic HCV infection can be treated efficiently and safely with DAA therapy in KT patients. Most patients retained stable kidney function and improved liver function. Tacrolimus dose had to be increased in most patients, potentially as a result of better liver function.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS)

  • Kuebler, Bernd|||0000-0002-4472-871X
  • Aran, Begoña|||0000-0002-5011-7755
  • Miquel-Serra, Laia|||0000-0001-8382-3341
  • Muñoz, Yolanda
  • Ars, Elisabet|||0000-0002-4118-4358
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Martí, Mercè|||0000-0002-1846-0043
  • Veiga, Anna|||0000-0002-0943-9904
  • Raya, Ángel|||0000-0003-2189-9775
A skin biopsy was obtained from a 25-year-old female patient with autosomal recessive Alport syndrome (ARAS) with the homozygous COL4A3 mutation c.345delG, p.(P166Lfs*37). Dermal fibroblasts were derived and reprogrammed by nucleofection with episomal plasmids carrying OCT3/4, SOX2, KLF4 LIN28, L-MYC and p53shRNA. The generated induced Pluripotent Stem Cell (iPSC) clone AS FiPS1 Ep6F-2 was free of genomically integrated reprogramming genes, had the specific homozygous mutation, a stable karyotype, expressed pluripotency markers and generated embryoid bodies which were differentiated towards the three germ layers in vitro. This iPSC line offers a useful resource to study Alport syndrome pathomechanisms and drug testing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Correction, The 2019 and 2021 International workshops on Alport syndrome

  • Daga, Sergio
  • Ding, Jie
  • Deltas, Constantinos|||0000-0001-5549-9169
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events, Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bruera, Sebastian
  • Suarez-Almazor, Maria E.
There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2-3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes

  • Palau, Vanesa|||0000-0002-3210-7924
  • Villanueva, Sofia
  • Jarrín, Josué|||0000-0001-9172-3383
  • Benito, David|||0000-0001-5413-5005
  • Márquez, Eva
  • Rodríguez García, Eva
  • Soler, María José|||0000-0003-3621-0766
  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Sans, Laia|||0000-0002-3628-9489
  • Soler, María José|||0000-0003-3621-0766
  • Pascual, Julio|||0000-0002-4735-7838
  • Barrios, Clara|||0000-0003-0492-4107
  • Riera Oliva, Marta|||0000-0003-4362-7965
Acute and chronic kidney lesions induce an increase in A Disintegrin And Metalloproteinase domain 17 (ADAM17) that cleaves several transmembrane proteins related to inflammatory and fibrotic pathways. Our group has demonstrated that renal ADAM17 is upregulated in diabetic mice and its inhibition decreases renal inflammation and fibrosis. The purpose of the present study was to analyze how Adam17 deletion in proximal tubules affects different renal structures in an obese mice model. Tubular Adam17 knockout male mice and their controls were fed a high-fat diet (HFD) for 22 weeks. Glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, and pro-inflammatory and pro-fibrotic markers were evaluated. Results showed that wild-type mice fed an HFD became obese with glucose intolerance and renal histological alterations mimicking a pre-diabetic condition; consequently, greater glomerular size and mesangial expansion were observed. Adam17 tubular deletion improved glucose tolerance and protected animals against glomerular injury and prevented podocyte loss in HFD mice. In addition, HFD mice showed more glomerular macrophages and collagen accumulation, which was prevented by Adam17 deletion. Galectin-3 expression increased in the proximal tubules and glomeruli of HFD mice and ameliorated with Adam17 deletion. In conclusion, Adam17 in proximal tubules influences glucose tolerance and participates in the kidney injury in an obese pre-diabetic murine model. The role of ADAM17 in the tubule impacts on glomerular inflammation and fibrosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease, Should We Individualize the Treatment?

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bolufer, Mónica|||0000-0002-3379-7031
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Barrios, Clara|||0000-0003-0492-4107
  • Palau, Vanesa|||0000-0002-3210-7924
  • Nevot Banús, Maria|||0000-0003-4947-4648
  • Pedreño-López, Sònia|||0000-0002-1919-3530
  • Senserrich, Jordi|||0000-0002-8021-1718
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Ballana, Ester|||0000-0002-5215-7363
Angiotensin converting enzyme 2 (ACE2) is a host ectopeptidase and the receptor for the SARS-CoV-2 virus, albeit virus-ACE2 interaction goes far beyond viral entry into target cells. Controversial data exists linking viral infection to changes in ACE2 expression and function, which might influence the subsequent induction of an inflammatory response. Here, we tested the significance of soluble ACE2 enzymatic activity longitudinally in nasopharyngeal swabs and plasma samples of SARS-CoV-2 infected patients, along with the induction of inflammatory cytokines. Release of soluble functional ACE2 increases upon SARS-CoV-2 infection in swabs and plasma of infected patients, albeit rapidly decreasing during infection course in parallel with ACE2 gene expression. Similarly, SARS-CoV-2 infection also induced the expression of inflammatory cytokines. These changes positively correlated with the viral load. Overall, our results demonstrate the existence of mechanisms by which SARS-CoV-2 modulates ACE2 expression and function, intracellular viral sensing and subsequent inflammatory response, offering new insights into ACE2 dynamics in the human upper respiratory tract and pointing towards soluble ACE2 levels as a putative early biomarker of infection severity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • González, Ester
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López, Diana
  • Martín-Gómez, Adoración
  • Garcia-Osuna, Rosa
  • Linares, Tania
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín, Nàdia
  • Barros, Xoana|||0000-0001-9690-9769
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Esparza, Noemí
  • Elias, Sandra
  • Coloma, Ana|||0000-0002-1773-9560
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Poch, Esteban|||0000-0002-6492-024X
  • Rodas, Lidia
  • Lozano, Víctor
  • Fernández-Fernández, Beatriz
  • Hernández, Eduardo
  • Martínez, Maria Isabel
  • Stanescu, Ramona Ionela
  • Moirón, José Pelayo
  • García Fernández, Nuria|||0000-0003-1082-0806
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Calero, Francesca|||0000-0002-5758-0769
  • Bonet Sol, Josep
  • Liaño, Fernando
  • Pascual, Julio|||0000-0002-4735-7838
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Praga, Manuel|||0000-0001-9270-1071
  • Fulladosa, Xavier|||0000-0003-1974-9874
  • Soler, María José|||0000-0003-3621-0766
Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy (DN). The objective of the current study was to investigate the kidney outcomes and survival in patients with biopsy diagnoses of DN and NDKD according to the presence of DR. We conducted an observational, multicentre and retrospective study of the pathological findings of renal biopsies from 832 consecutive patients with diabetes from 2002 to 2014 from 18 nephrology departments. The association of DR with kidney replacement therapy (KRT) or survival was assessed by Kaplan-Meier and Cox regression analyses. Of 832 patients with diabetes and renal biopsy, 768 had a retinal examination and 221/768 (22.6%) had DR. During a follow-up of 10 years, 288/760 (37.9%) patients with follow-up data needed KRT and 157/760 (20.7%) died. The incidence of KRT was higher among patients with DN (alone or with NDKD) and DR [103/175 (58.9%)] than among patients without DR [88/216 (40.7%), P <.0001]. The incidence of KRT was also higher among patients with only NDKD and DR than among those without DR [18/46 (39.1%) versus 79/331 (23.9%), P <.0001]. In multivariate analysis, DR or DN were independent risk factors for KRT {hazard ratio [HR] 2.48 [confidence interval (CI) 1.85-3.31], P <.001}. DN (with or without DR) was also identified as an independent risk factor for mortality [HR 1.81 (CI 1.26-2.62), P =.001]. DR is associated with a higher risk of progression to kidney failure in patients with histological DN and in patients with NDKD.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Osteogenic commitment of Wharton’s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

  • Cabrera Perez, Raquel
  • Gámez-Valero, Ana
  • Rojas-Márquez, Raquel
  • Borràs, Francesc Enric
  • Roura, Santiago
  • Vives Armengol, Joaquim
  • Monguió-Tortajada, Marta
Cèl·lules estromals mesenquimals; Gelatina de Wharton; Diferenciació osteogènica, Células estromales mesenquimales; Gelatina de Wharton; Diferenciación osteogénica, Mesenchymal stromal cells, Wharton’s jelly; Osteogenic differentiation, Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions., Work in our laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788), Fundació la Marató de TV3 (expedient number: 122831), and ISCIII-REDinREN (RD16/0009 Feder Funds), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational programme (European Regional Development Fund) 2014-2020. FEB is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, supported by the Health Department of the Catalan Government (Generalitat de Catalunya). Our laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Groups (ref. 2017-SGR-719, 2017-SGR-301 and 2017-SGR-483).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Safety of Obtaining an Extra Biobank Kidney Biopsy Core

  • Bermejo Garcia, Sheila
  • García Carro, Clara
  • Mast, Richard
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • León Román, Juan
  • Bolufer Cardona, Monica
  • Gabaldon Dominguez, Alejandra
  • Serón Micas, Daniel
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
Biobank; Chronic kidney disease; Kidney biopsy, Biobanco; Enfermedad renal cronica; Biopsia renal, Biobanc; Malaltia renal crònica; Biòpsia de ronyó, Background and objectives: Kidney biopsy (KB) is the “gold standard” for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. Material and methods: Prospective observational study of KBs performed at Vall d’Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications. Results: A total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506–3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (n = 25) required blood transfusion, 1.4% (n = 3) had severe hematomas, 2.3% (n = 5) required embolization, and 0.5% (n = 1) presented arterio-venous fistula. An increased risk for complication was independently associated with obtaining a single kidney core (vs. 2 and 3 cores) (p = 0.021). Conclusions: KB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports., The authors are current recipients of research grant from Red de Investigación Renal (REDINREN, RD16/0009/0030). (RICORS, RD21/0005/0016).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • León Román, Juan
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Vergara Arana, Ander
  • Gabaldon Dominguez, Alejandra
  • Torres Rodriguez, Irina Betsabe
  • Bury, Roxana
  • Baldallo, Cinthia
  • Serón Micas, Daniel
  • Soler Romeo, Maria Jose
COVID-19; Malaltia renal crònica, COVID-19; Enfermedad renal crónica, COVID-19; Chronic kidney disease, Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder (FI17/00257 and EIN2020-1123381) and Redinren (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

  • Oleas, Diana
  • Bolufer Cardona, Monica
  • Agraz Pamplona, Irene
  • Gabaldon Dominguez, Alejandra
  • Bury, Roxana
  • Espinel Garuz, María Eugenia
  • Serón Micas, Daniel
  • García Carro, Clara
  • Soler Romeo, Maria Jose
  • Muñoz Couselo, Eva
  • Felip Font, Enriqueta
Nefritis intersticial aguda; Inhibidors de punts de control; Biòpsia de ronyó, Nefritis intersticial aguda; Inhibidores de puntos de control; Biopsia renal, Acute interstitial nephritis; Checkpoint inhibitors; Kidney biopsy, Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d’Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, ISCIII (PI17/00257) and Redinren (RD16/0009/0030). M.B. performed this work as the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

  • Vergara Arana, Ander
  • Bermejo Garcia, Sheila
  • Azancot Rivero, M Antonieta
  • Sanchez Fructuoso, Ana Isabel
  • Sánchez de la Nieta, M. Dolores
  • Agraz Pamplona, Irene
  • Soler Romeo, Maria Jose
  • García-Carro, Clara
Malaltia renal crònica; Diabetis mellitus; Malaltia renal diabètica, Enfermedad renal crónica; Diabetes mellitus; Enfermedad renal diabética, Chronic kidney disease; Diabetes mellitus; Diabetic kidney disease, Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder—Instituto de Salud Carlos III (PI17/00257) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

  • Vergara Arana, Ander
  • Molina Van den Bosch, Mireia
  • Toapanta Gaibor, Nestor Gabriel
  • Villegas, Andrés
  • Sánchez-Cámara, Luis
  • Soler Romeo, Maria Jose
  • de Sequera, Patricia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiàlisi; Mortalitat, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiálisis; Mortalidad, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haemodialysis; Mortality, Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination., The authors are current recipients of FONDOS DE INVESTIGACIÓN SANITARIA—FEDER (ISCIII) PI17/00257, REDINREN RD16/0009/0030, RD/16/0009/0026, and EIN2020-112338.